*Article*

# Model Substrate/Inactivation Reactions for MoaA and Ribonucleotide Reductases: Loss of Bromo, Chloro, or Tosylate Groups from C2 of 1,5-Dideoxyhomoribofuranoses upon Generation of an $\alpha$-Oxy Radical at C3 [†]

**Stanislaw F. Wnuk [1,*]** , **Mukesh M. Mudgal [1]** , **Ireneusz Nowak [2]** and **Morris J. Robins [2,*]**

[1]    Department of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA; mmudg001@fiu.edu

[2]    Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602-5700, USA; i_nowak@hotmail.com

*    Correspondence: wnuk@fiu.edu (S.F.W.); morrisrobins@gmail.com (M.J.R.)

†    Dedicated to the inspiring chemist Professor Piet Herdewijn.

check for updates

**Abstract:** We report studies on radical-initiated fragmentations of model 1,5-dideoxyhomoribofuranose derivatives with bromo, chloro, and tosyloxy substituents on C2. The effects of stereochemical inversion at C2 were probed with the corresponding arabino epimers. In all cases, the elimination of bromide, chloride, and tosylate anions occurred when the 3-hydroxyl group was unprotected. The isolation of deuterium-labeled furanone products established heterolytic cleavage followed by the transfer of deuterium from labeled tributylstannane. In contrast, 3-*O*-methyl derivatives underwent the elimination of bromine or chlorine radicals to give the 2,3-alkene with no incorporation of label in the methyl vinyl ether. More drastic fragmentation occurred with both of the 3-*O*-methyl-2-tosyloxy epimers to give an aromatized furan derivative with no deuterium label. Contrasting results observed with the present anhydroalditol models relative to our prior studies with analogously substituted nucleoside models have demonstrated that insights from biomimetic chemical reactions can provide illumination of mechanistic pathways employed by ribonucleotide reductases (RNRs) and the MoaA enzyme involved in the biosynthesis of molybdopterin.

## 1. Introduction

Ribonucleotide reductases (RNRs) effect conversion of nucleoside 5′-(di- or tri)phosphates into their 2′-deoxy counterparts and thereby provide the only de novo access to the monomeric precursors for DNA replication and repair [1]. Depletion of these crucial deoxynucleotide pools by inhibition of RNRs presents an inviting approach for rational drug design [2,3]. Mechanism-based inactivation of RNRs has been observed with 2′-chloro [4] and 2′-azido [5–8] analogues of pyrimidine nucleoside 5′-(di- or tri)phosphates, and the potent inactivator 2′-deoxy-2′,2′-difluorocytidine (gemcitabine) is a primary drug for the treatment of pancreatic and non-small cell lung cancers [2,3,9,10].

Abstraction of H3′ from the ribosyl moiety of the substrate in **A** (Figure 1, X = OH) by a thiyl radical (•SCys439) to give **B** (X = OH) is the postulated initial step of the RNR-catalyzed deoxygenation of ribonucleotides [1]. Enzyme-assisted loss of water from C2′ in **B** would produce the 3′-keto C2′

radical in **C**, and further electron and hydrogen-atom transfers via **D** and **E** would complete the conversion of substrate into the product 2′-deoxynucleotide in **F** [11,12].



**Figure 1.** Mechanisms proposed for reduction of ribonucleoside diphosphates and inactivation of RDPRs by 2′-chloro analogues [1].

Abstraction of H3′ from a 2′-chloro-2′-deoxynucleotide inactivator was proposed to convert **A** (X = Cl) to **B** (X = Cl). Spontaneous loss of chloride in **B** (X = Cl) followed by hydrogen transfer from the thiol to C2′ in **C** and electron transfer to the dithiol would produce the identical 3′-keto-2′-deoxynucleotide in **D** as with the substrate nucleotide [1,4,6]. Changes at the active site caused by the loss of $Cl^-$ and $H^+$ from the inactivator (rather than enzyme-assisted removal of $H_2O$ from the substrate) were invoked to rationalize its dissociation from **D** of the enzyme. Successive β-eliminations of B(ase) and pyrophosphate would generate 2-methylene-3(2*H*)-furanone (**G**), a Michael acceptor, which could affect covalent alkylating of the RNR and cause mechanism-based inactivation. Incubation of gemcitabine 5′-diphosphate with RDPRs (ribonucleoside diphosphate reductases) caused inactivation of both of the R1 and R2 subunits [13–17].

The initial mechanistic steps are compatible with theoretical modeling studies [18,19], with the biomimetic chemical experiments reported by Giese [20] and Robins [21,22], and with Stubbe's enzymatic studies with gemcitabine [13–17] and 2′-deoxy-2′-fluoromethylenecytidine [23,24]. However, the detection of ribosyl-based radicals during RNR-catalyzed deoxygenation of substrates remained elusive [25]. Two sets of EPR signals were observed during kinetic studies with the E441Q mutant of *E. coli* class I RDPR and cytidine 5′-diphosphate [26]. Signals attributed to the initially detected radical were consistent with those from a disulfide radical anion [27], and those from the second were compatible with appearance of a nucleotide-based radical of the semidione type [28]. The latter-type of signals was observed during the inactivation of RNR by gemcitabine nucleotides [16].

Giese [20] and Robins [21,22] designed chemical models to simulate such initiation/elimination cascades that begin with the generation of a C3′ radical during the reduction and mechanism-based inactivation mediated by RDPRs. Lenz and Giese employed photochemical fragmentation of adenosine 3′-selenoesters in aqueous methanol to generate C3′ radicals containing a 3′-hydroxyl group. The addition of an acetate buffer to the photolysis solution enhanced the rate of cleavage of water

from C2′ as predicted for base-promoted assistance by an enzymatic carboxylate group [20]. Robins et al. designed 6′-*O*-nitro-2′-substituted homonucleoside derivatives that produced 6′-oxyl radicals upon treatment with tributylstannane/AIBN. The O6′ radicals were positioned to abstract H3′ with the generation of C3′ radicals containing a 3′-hydroxyl group. Fragmentation of a 2′-*O*-tosyl derivative occurred by anionic elimination [29], whereas a 2′-chloro analogue fragmented by a radical elimination pathway [30]. Nucleoside derivatives with a 2′-(azido, bromo, chloro, iodo, or methylthio) group also underwent elimination of a radical species upon generation of a radical center at C3′ [31].

Begley recently reported trapping of intermediates in the MoaA-catalyzed biosynthesis of molybdopterin using 2′-deoxyguanosine 5′-triphosphate and its 2′-chloro-2′-deoxy derivative as alternative substrate analogs [32]. A 5′-deoxyadenosyl radical cofactor abstracts H3′ from the GTP substrate (and also from the 2′-chloro ribo analog) with generation of C3′ radicals containing a 3′-hydroxyl group. The homolytic elimination of chlorine from C2′ would give the 2′,3′-enol, and β-eliminations of triphosphate and guanine would produce 2-methylene-3(2*H*)furanone (**G**, Figure 1) as described by us in 1996 [30].

Herein, we report that 1,5-dideoxyhomoribofuranose derivatives containing a 3-hydroxyl group with a bromo, chloro, or tosylate substituent at C2 fragment with loss of bromide, chloride, or tosylate anions upon generation of a radical center at C3. The ionic fragmentations of both ribo and arabino epimers were essentially equivalent. These model reactions provide additional experimental data that allow further illumination of mechanisms employed by ribonucleotide reductases [18,19] and the MoaA enzyme [32] involved in molybdopterin biosynthesis.

## 2. Results

### 2.1. Synthesis of 1,4-Anhydrohexitol Models

Methyl 5-deoxy-2,3-*O*-isopropylidene-β-D-*ribo*-hexofuranoside (**1**, Scheme 1) was prepared efficiently in 7 steps (~40% overall yield) from 1,2-*O*-isopropylidene-α-D-glucose [29]. Benzoylation of **1** and anomeric deoxygenation of **2** (BF₃•OEt₂/Et₃SiH) [33,34] gave a mixture of **4** and **3** (partial loss of the isopropylidene group). Reprotection of **3** gave the 1,4-anhydroalditol [35] **4** (44% overall from **1**). Successive debenzoylation of **4**, iodination of **5**, and deprotection of **6** gave 6-iodo furanitol **7** (53% from **4**). Nitrate displacement of iodide from **7** (AgNO₃/CH₃CN) gave 1,4-anhydro-5-deoxy-6-*O*-nitro-D-*ribo*-hexitol (**8**, 89%). Tin-mediated tosylation [36] of **8** gave a regioisomeric mixture from which the major 2-*O*-tosyl isomer **9** (48%) was isolated.



**Scheme 1.** Reagents and Conditions: (a) BzCl/Et₃N/CH₂Cl₂/0 °C; (b) Et₃SiH (3 equiv)/BF₃•OEt₂/CH₂Cl₂; (c) TsOH/acetone/2,2-dimethoxypropane; (d) KOH/MeOH; (e) Ph₃P/I₂/imidazole/toluene/Δ; (f) HCl/H₂O/MeOH; (g) AgNO₃ (2 equiv)/CH₃CN/rt/48 h; (h) Bu₂SnO/TsCl (6 equiv)/Et₃N/MeOH.

Tin-mediated benzylation of **8** with *p*-methoxybenzyl (PMB) chloride gave a mixture from which the 3-*O*-PMB regioisomer **10** (Scheme 2) was isolated. Tosylation of **10** followed by removal of the PMB group from **15** (ceric ammonium nitrate (CAN)) gave an alternative route to **9** (54% from **10**). Mitsunobu chlorination of **10** (freshly prepared HCl•pyridine) gave the protected 2-chloro-*arabino*-hexofuranose **11** (62%). Analogous bromination of **10** with freshly prepared HBr•pyridine gave the 2-bromo product **12** (49%). Debenzylation of **11** and **12** (CAN) gave **13** (78%) and **14** (79%), respectively.



**Scheme 2.** Reagents and Conditions: (a) Bu$_2$SnO (1.1 equiv)/PMBCl (2 equiv)/DMF/Δ; (b) Ph$_3$P/DIAD/pyridine•HCl (3 equiv) or pyridine•HBr (1.5 equiv)/THF/rt/22 h; (c) TsCl/pyridine/rt/16 h; (d) Ph$_3$P/DIAD/BzOH/THF/−50 °C; (e) CAN (3 equiv)/MeCN/H$_2$O/rt/22 h; (f) KOH/MeOH; (g) TfCl (1.2 equiv)/DMAP (2.5 equiv)/CH$_2$Cl$_2$/0 °C/1 h; (h) LiCl (5 equiv/rt/5 h) or LiBr (5.5 equiv/rt/7 h)/DMF.

The 2-chloro and 2-bromo-D-*ribo*-hexofuranoses **20** and **22** (Scheme 2) were prepared from **10** by double inversion. Mitsunobu treatment of **10** (BzOH) produced the 2-*O*-benzoyl-D-*arabino*-hexofuranose **16a**. Debenzoylation of **16a** and treatment of **16b** with TfCl/DMAP gave the reasonably stable triflate **17b**. Displacement of triflate (LiCl or LiBr) and debenzylation (CAN) of the resulting **19** or **21** gave the 2-chloro or 2-bromo-D-*ribo*-hexofuranose **20** or **22**. Tosylation of **16b** followed by debenzylation of **17a** gave the 2-*O*-tosyl-*arabino* product **18**.

Tin-mediated methylation of **8** produced **23** and **24** (Scheme 3) and the major 3-*O*-methyl isomer **23** (38%) was isolated and tosylated to give the *ribo* tosylate **25**. Mitsunobu treatment of **23** (BzOH), debenzoylation of **26**, and tosylation of **27** gave *arabino* tosylate **30**. Mitsunobu halogenations of **23** gave the 3-*O*-methyl-D-*arabino* 2-chloro **28** and 2-bromo **29** analogues. Triflation of **27** and displacement of triflate from **31** with LiCl or LiBr gave the *ribo* 2-chloro **32** and 2-bromo **33** compounds.

**Scheme 3.** Reagents and Conditions: (a) $Bu_2SnO/MeI/DMF/\Delta$; (b). TsCl/pyridine; (c) $Ph_3P$/DIAD/BzCl/ THF/50 °C; (d) $Ph_3P$/DIAD/pyridine•HCl or pyridine•HBr (1.5 equiv)/THF/rt/18 h; (e) KOH/MeOH; (f) TfCl/DMAP/$CH_2Cl_2$/0 °C; (g) LiCl (5 equiv) or LiBr (3 equiv)/DMF/rt/5 h.

## 2.2. Radical Generation Studies

Treatment of the 6-*O*-nitro-2-*O*-tosyl *ribo* compound **9** with $Bu_3SnH$/AIBN/toluene/95 °C for 1 h gave an equilibrating mixture of the 3-oxo product **34a** [(*R*)-2-(2-hydroxyethyl)-3(2*H*)-dihydrofuranone] and its cyclic hemiacetal **35a** (66%, ~1:1; $^1H$ and $^{13}C$ NMR) (Scheme 4). A minor amount (19%) of the 6-hydroxy-2-*O*-tosyl byproduct resulting from hydrogen transfer to the 6-oxyl radical without elimination of tosylate also was isolated (Table 1, entry 1, footnote d). The $^{13}C$ NMR spectrum of the mixture had a signal for the carbonyl carbon of **34a** at 215.9 ppm and one for the hemiacetal carbon of **35a** at 114.9 ppm. Analogous treatment of **9** with $Bu_3SnD$ gave the 2-deuterio epimers (2*R/S*, ~1:1) of **34b/35b** (71%, ~1:1; entry 2). The $^1H$ NMR spectrum of **34b/35b** corresponded to that of **34a/35a** with ~50% reduction of the integrated intensity for the H2/2′ signals and simplification of the H1/1′ signals. The $^{13}C$ NMR spectrum of **34b/35b** showed triplets from splitting with deuterium (1:1:1 intensity) at 36.7 and 38.9 ppm for C2. MS and HRMS spectra showed ~95% incorporation of deuterium. Benzoylation of the **34a/35a** mixture provided a stable ketone benzoate **36a**, and benzoylation of **34b/35b** gave **36b** (2-deuterio epimers).



**Scheme 4.** Biomimetic studies with 6-*O*-nitro-1,4-anhydrohexitols.

**Table 1.** Products from 6-*O*-nitro-1,4-anhydrohexitols [a].



| Entry | Substrate | | | Reagent | Products | Ratio [b] | Yield [c] (%) |
|---|---|---|---|---|---|---|---|
| | No | X | Y | | | | |
| 1 | **9** | OTs | H | Bu₃SnH | **34a:35a** | 1:1 | 66 [d] |
| 2 | **9** | OTs | H | Bu₃SnD | **34b:35b** | 1:1 | 71 [d] |
| 3 | **20** | Cl | H | Bu₃SnH | **34a:35a** | 1:1 | 81 |
| 4 | **20** | Cl | H | Bu₃SnD | **34b:35b** | 1:1 | 67 |
| 5 | **22** | Br | H | Bu₃SnH | **34a:35a** | 1:1 | 64 |
| 6 | **22** | Br | H | Bu₃SnD | **34b:35b** | 1:1 | 68 |
| 7 | **13** | H | Cl | Bu₃SnH | **34a:35a** | 1:1 | 97 |
| 8 | **13** | H | Cl | Bu₃SnD | **34b:35b** | 1:1 | 82 |
| 9 | **14** | H | Br | Bu₃SnH | **34a:35a** | 1:1 | 67 [e] |
| 10 | **14** | H | Br | Bu₃SnD | **34b:35b** | 1:1 | 54 [e] |
| 11 | **18** | H | OTs | Bu₃SnH | **34a:35a** | 1:1 | 93 |
| 12 | **18** | H | OTs | Bu₃SnD | **34b:35b** | 1:1 | 93 |

[a] Reactions were performed on 0.057 mmol (**9** or **18**), 0.094 mmol (**13** or **20**), or 0.078 mmol (**14** or **22**) of substrates (0.029–0.047 M) with 5 equiv. of Bu₃SnH(D) and 2 equiv. of AIBN in toluene (95 °C, 1–2 h.). [b] Determined by ¹H NMR. [c] Isolated yields. [d] 1,5-Dideoxy-2-*O*-tosyl-D-ribohexofuranose also formed (19%). [e] Hydrodebrominated (2-deoxy) byproducts were also isolated (10–15%).

The role of the proton on the 3-hydroxyl group was probed. Treatment of the 3-*O*-methyl-6-*O*-nitro-2-*O*-tosyl ribo substrate **25** produced 2-(2-hydroxyethyl)-3-methoxyfuran (**37**, 63%) plus the 6-hydroxy byproduct **38** (22%) (Scheme 5; Table 2, entry 1). Treatment of **25** with Bu₃SnD gave **37** and **38** with no incorporation of deuterium (entry 2) and no epimerization at C3 [37]. Tosylate **25** was thermally stable in toluene at 95 °C. Treatment of the arabino 3-*O*-methyl-2-*O*-tosyl substrate **30** with Bu₃SnH gave **37** (51%) plus byproduct **39** (38%) (entry 7). Treatment of **30** with Bu₃SnD produced **37** and **39** without incorporation of deuterium or epimerization at C3 (entry 8).

Treatment of the 3-*O*-methyl-2-chloro (**32**) and 2-bromo (**33**) ribo substrates with Bu₃SnD resulted in formation of vinyl ether **40** with no incorporation of deuterium (entries 3 and 4). The ¹³C NMR spectrum of **40** had olefinic signals at 90.2 and 157.7 ppm, and the ¹H NMR spectrum had olefinic proton signals at 4.60–4.70 ppm. Treatment of the arabino 3-*O*-methyl-2-chloro (**28**) and bromo (**29**) compounds with Bu₃SnD also resulted in elimination of a halogen atom to give vinyl ether **40** with no incorporation of deuterium (entries 5 and 6).



**Scheme 5.** Biomimetic studies with 3-*O*-methyl-6-*O*-nitro-1,4-anhydrohexitols. Reagents and Conditions: (a) Bu₃SnH(D)/AIBN/toluene/95 °C.

Similar treatment of the 2-chloro (**20**) and 2-bromo (**22**) ribo analogs produced the same keto/hemiacetal mixture (**34a**/**35a**, ~1:1; 81%, entry 3; and 64%, entry 5). Treatment of **20** (and **22**) with Bu₃SnD gave **34b**/**35b** as 2(*R/S*)-deuterio epimers (entries 4 and 6). Toluene solutions of **9**, **20**, and **22** (without Bu₃SnH or AIBN) were heated independently at 95 °C for 4 h (also at 110 °C).

Unchanged starting materials were recovered almost quantitatively, which confirmed their thermal stability under these conditions and excluded the possibility of initial dissociation of a substituent from C2. Compound **9** also was stable at 95 °C for 2.5 h in DMF.

**Table 2.** Products from 3-*O*-methyl-6-*O*-nitro-1,4-anhydrohexitols [a].

| Entry | Substrate | | | Reagent | Product | Yield [b] (%) |
|---|---|---|---|---|---|---|
| | **No** | **X** | **Y** | | | |
| 1 | **25** | OTs | H | Bu$_3$SnH | **37** | 63 [c] |
| 2 | **25** | OTs | H | Bu$_3$SnD | **37** | 61 [c] |
| 3 | **32** | Cl | H | Bu$_3$SnD | **40** | 55 |
| 4 | **33** | Br | H | Bu$_3$SnD | **40** | 37 [d] |
| 5 | **28** | H | Cl | Bu$_3$SnD | **40** | 63 |
| 6 | **29** | H | Br | Bu$_3$SnD | **40** | 47 [d] |
| 7 | **30** | H | OTs | Bu$_3$SnH | **37** | 51 [e] |
| 8 | **30** | H | OTs | Bu$_3$SnD | **37** | 50 [e] |

[a] Reactions were performed with 0.055 mmol (**25** or **30**), 0.088 mmol (**28** or **32**), or 0.074 (**29** or **33**) of substrates (0.027–0.044 M), 5 equiv. of Bu$_3$SnH(D), and 2 equiv. of AIBN in toluene for 1.5 h at 95 °C. [b] Isolated yields. [c] Compound **38** (22%) also was isolated. [d] Hydrodebrominated 2-deoxy byproducts also were isolated (~15–25%). [e] Compound **39** (38%) also was isolated.

The arabino 2-(chloro, bromo, and tosyloxy) compounds (**13**, **14**, and **18**) were subjected to the conditions used with the ribo epimers to probe the effect of stereochemical inversion at C2. The same equilibrating mixtures of **34a/35a** were produced with Bu$_3$SnH (entries 7, 9, and 11) and the epimeric 2-deuterio derivatives **34b/35b** were generated with Bu$_3$SnD (entries 8, 10, and 12). Incorporation of deuterium into the ketone/hemiacetal products demonstrated that elimination of tosylate, chloride, and bromide anions occurred with all three of the arabino compounds. Enhanced yields of the tautomeric product mixtures were isolated with the chloro (**13**, entries 7 and 8) and tosylate (**18**, entries 11 and 12) substrates. Byproduct formation was not observed with **18**, whereas it was formed (~19%) with the ribo substrate **9** (entries 1 and 2, footnote d). Some hydrodebromination also was detected with the arabino 2-bromo epimer **14** (entries 9 and 10, footnote e).

Samples of **9**, **13**, **14**, and **18** were treated with Bu$_3$SnH in deuterated toluene. Fragmentation of tosylate **9** in toluene-$d_8$ (Bu$_3$SnH/AIBN) at 75 °C was 90–95% complete in 2.5 h (TLC and $^1$H NMR) and produced **34a/35a** (80–85%) as sole products with no incorporation of deuterium. Analogous treatment of **9** at 55 °C for 2.5 h resulted in ~50% fragmentation. Treatment of the arabino tosylate **18** and chloride **13** substrates at 75 °C showed that the fragmentation of **18** was slightly faster than that of **13** (Figure 2; $^1$H NMR spectra were used for substrate/products ratios, see the Experimental Section). Fragmentation of the ribo tosylate **9** to give **34a/35a** proceeded at a rate similar to that determined with the arabino chloride **13**. Treatment of the arabino bromide **14** at 75 °C produced **34a/35a** plus 2-deoxy byproduct mixtures with $^1$H NMR spectra that were too complex for quantitative analysis.



**Figure 2.** Pseudo-first order plots for conversion of **13** (chloro) and **18** (tosylate) into **34a/35a.**

## 3. Discussion

The mechanism proposed [1] for conversion of ribonucleoside 5′-diphosphates (**A**, X = OH) to 2′-deoxynucleotides (**F**) by RDPRs (Figure 1, inside the boxes) is supported by biochemical, chemical, and theoretical modeling studies. However, the enzymatic processing of 2′-chloro analogs (**A**, X = Cl) could cause inactivation by different chemistry. Incubation of a 2′-chloro-2′-deoxynucleoside 5′-diphosphate with RDPR produced 2-methylene-3(2*H*)furanone (**G**), a Michael acceptor that could cause time-dependent enzyme inactivation. Stubbe rationalized [1] that spontaneous elimination of a chloride anion (and a proton) at the active site (rather than the enzyme-assisted removal of HOH with substrates) could cause active site changes resulting in dissociation of the 2′-deoxy-3′-oxo intermediate from **D** (Figure 1). Successive β-eliminations of pyrophosphate from C5′ and the base from C1′ could generate **G** in solution. However, the identical 3′-keto intermediate in **D** was postulated in the substrate to product sequence, which makes the presence of chloride and a proton the only difference for the inactivation sequence.

We reasoned that elimination of a chlorine atom from the initial C3′ radical was more likely. The electronegative character of C1′ would make the elimination of chloride (with generation of positive character at C2′) unfavorable, whereas loss of a chlorine atom with generation of a C2′ radical was well precedented [38], and generation of an enol would be energetically advantageous. Elimination of a chlorine atom (rather than chloride) at the active site could have serious consequences. The chlorine radical could attack a sulfhydryl group and the resulting sulfenyl chloride could react with nucleophilic groups in the enzyme or undergo hydrolysis to a sulfenic acid. Chlorine-atom abstraction of hydrogen from an amino acid residue (and resulting radical processes) and other chlorine-radical reactions would be possible, whereas such events would not occur with a ground state chloride anion. Radical-induced disruption of active-site architecture provides a more plausible explanation for dissociation of the 2′-deoxy-3′-oxo intermediate from **D**.

We have shown [31] that leaving-group radical stability is crucial for substituent elimination from C2′ upon generation of a radical at C3′. Treatment of 2′-(azido, bromo, chloro, iodo, or methylthio)-2′-deoxy-3′-*O*-phenoxythiocarbonyl nucleosides (**H**a, Figure 3) with BuSnH resulted in generation of C3′ radicals **I**a that underwent elimination of a radical from C2′ with formation of 2′,3′-unsaturated derivative **J**. In contrast, treatment of the 2′-(fluoro, mesyloxy, or tosyloxy)-3′-thionocarbonates **H**b generated C3′ radicals **I**b that abstracted hydrogen from the stannane to give 3′-deoxy-2′-(fluoro, mesyloxy, or tosyloxy) derivatives **K**b. Elimination of a radical from C2′ of **I**a gave **J**, whereas homolytic scission to release a high-energy fluorine atom or a mesyloxy or tosyloxy radical is energetically prohibitive—and did not occur. In those cases, abstraction of hydrogen from the stannane by the C3′ radical **I**b gave the reduced products **K**b.



Series a: X = N₃, Br, Cl, I, SMe; b: X = F, OMs, OTs

**Figure 3.** Bu₃SnH/AIBN/Δ treatment of 3′-thionocarbonates.

Because the radicals **I** did not contain a 3′-hydroxyl group, we prepared model compounds that were more closely related to the natural substrates for RDPR-catalyzed 2′-deoxygenations. Treatment of the adenine 6′-*O*-nitro-2′-*O*-tosyl **L** and uracil 6′-*O*-nitro-2′-chloro **M** analogues with Bu₃SnD/AIBN/Δ generated the 6′-oxyl radicals **N** by attack of a stannyl radical at nitrate oxygen (Figure 4). Intramolecular

abstraction of H3′ from **N** gave the C3′ radicals **O** or **S**. Loss of the proton from the 3′-hydroxyl group of **O** and elimination of the 2′-tosylate (with shift of the unpaired electron from C3′ to C2′ and generation of the O = C3′ double bond) would drive the overall elimination of toluenesulfonic acid from **O** to produce **P**. Deuterium transfer from the stannane to C2′ of **P** followed by elimination of the trans proton/deuteron and adenine from **Q** would give the observed 2-(2-hydroxyethyl)-3(2*H*)-furanone (**R**) containing deuterium at C4 (C2′ from the nucleoside). In contrast, loss of the chlorine atom from **S** would give enol **T**, which could undergo 1,4-elimination to **U** with no incorporation of deuterium (as observed). This demonstrated the distinct differences between TsO–C2′ bond cleavage by a two-electron heterolysis (in **O**) and cleavage of the chlorine–C2′ bond by a one-electron homolysis (in **S**) [21,29,30].



**Figure 4.** Heterolytic (path a, TsO⁻) and homolytic (path b, Cl•) eliminations from radicals containing a 3′j32;-hydroxyl group [21,29,30].

Barton's nitrite ester [39] and Wagner's δ-substituted aryl ketone [40] photolysis studies showed a strong preference for six-membered transition states for hydrogen abstraction by oxyl radicals. Fraser-Reid employed that [1,5]-hydrogen shift with oxyl radicals generated from carbohydrate nitrate esters and Bu₃SnH [41]. Radical-induced loss of ⁻OTs and H⁺ (Figure 4, path a) is also analogous to an ionic LiEt₃BH-promoted rearrangement of 2′-*O*-tosyladenosine. Removal of the 3′-hydroxyl proton by Et₃BH⁻ initiated a [1,2]-hydride shift from C3′ to C2′ with displacement of tosylate from C2′ [42,43]. That rearrangement occurred also with 2′-chloro-2′-deoxyadenosine, but at a lower rate with the poorer leaving group (chloride).

Theoretical modeling [18,44] of RDPR-catalyzed 2′-deoxygenation invoked hydrogen bonding from the 3′-OH to a carboxylate group and from H-donors to 2′-OH. Analogous attraction between the cis 3-OH in **9** and a tosylate oxygen atom was considered for possible assistance of the heterolytic cleavage of the TsO–C2 linkage. However, treatment of the arabino tosylate **18** (no cis 3-OH) gave the same **34b**/**35b** mixture in higher yield (93%) than with **9** (~70%). Byproduct with a hydroxyl group at C6 and tosylate at C2 was isolated (~19%) from treatment of **9**, but no such arabino byproduct was observed with **18**. These results are more consistent with a greater population of the C2-endo/C3-exo conformation range in **9** (reduction of strain with the 2-tosylate group) that would make a six-membered transition state for intramolecular abstraction of H3 by the 6-oxyl radical less favorable. Enhanced abstraction of deuterium from the stannane by the 6-oxyl radical would then occur to produce more of the byproduct. Greater C2-exo/C3-endo populations in **18** (reduction of strain between the arabino tosylate at C2 and the side chain at C4) would enhance the approach of the 6-oxyl radical for H3 abstraction and elimination of tosylate from the C3 radical to produce **34b**/**35b** in higher yield (93%).

Thus, noteworthy mechanistic changes were observed within our model series. Anionic elimination of tosylate from C2′ of a nucleoside occurred (Figure 4, pathway a), whereas radical elimination of a chlorine atom (pathway b) was preferred. However, treatment of our ribo anhydroalditol tosylate **9**, chloro **20**, or bromo **22** substrates produced the same 2-deuterio-3-ketone **34b** and hemiacetal **35b**

mixture. The arabino chloro **13** and bromo **14** epimers also gave **34b/35b** (plus some hydrodebromination with **14**). In every case, the loss of bromide or chloride anions from an intermediate C3 radical resulted in formation of deuterium-labeled materials rather than homolytic loss of a halogen atom to give the unlabeled alkene. The absence of an electronegative nucleobase on C1 (C1 is a $-CH_2-$ moiety in the anhydroalditol models) allowed elimination of an anion from C2 when loss of the 3-hydroxyl proton could generate an O = C3 double bond.

Radical elimination occurred with the 2-chloro-3-*O*-methyl ribo **32** and arabino **28** substrates to give vinyl ether **40**. Both 2-bromo-3-*O*-methyl ribo **33** and arabino **29** epimers also gave **40** (plus hydrodebrominated byproduct). Thus, when loss of the 3-hydroxyl proton and generation of a 3-ketone was prevented, elimination of a halogen atom occurred.

Ramos questioned our choice of toluene as solvent and lack of a basic residue in our prior nucleoside model studies and stated: "we concluded that the nature of the leaving substituent can be controlled; it will be anionic or radical depending on the presence or absence of a basic residue capable of deprotonating the 3'-HO group. In the enzyme, such functionality does exist, and so it can be concluded that the enzyme indeed eliminates anions, and not radicals" [19].

Clearly, the elimination of an anion is possible without a basic residue present in our current anhydroalditol models. Siegbahn [18] calculated a dielectric constant of $\varepsilon \sim 4$ in the region of the enzyme active site, which is approximated much more closely by that of toluene ($\varepsilon \sim 2.4$) than that of the aqueous methanol solutions ($\varepsilon > 40$) used by Lenz and Giese [20]. Thus, the intrinsic electronic status of the anomeric carbon C1' (inductively negative in nucleosides) or C1 (inductively positive in anhydroalditols) as well as the nature of the leaving substituent (X• or A⁻) are major factors that control heterolytic elimination of an anion or homolytic elimination of a radical in biomimetic model reactions—and such factors also likely play a key role in enzyme-initiated inactivation processes.

Begley [32] also has invoked our elimination of a chlorine atom [30] upon abstraction of H3' from 2'-chloro-2'-deoxyguanosine triphosphate by a 5'-deoxyadenosyl radical cofactor in MoaA. His 2'-deoxy-3'-ketone underwent the sequential β-eliminations [30] of triphosphate and guanine to give the same 2-methylene-3(2*H*)furanone (**G**, Figure 1) that could cause inactivation of RDPRs. Both of our ribo **32** and arabino **28** 2-chloro epimers gave vinyl ether **40**, whereas Begley's arabino epimer remained unchanged during incubation with MoaA. The cis,cis configuration of H3'/Cl/guanine in his arabino isomer might restrict conformational ranges that would favor binding with MoaA, and/or hinder approach of the 5'-deoxyadenosyl cofactor toward H3'. As discussed above, the different product/byproduct ratios in our fragmentations of **9** and **18**, and **25** and **30** might result from such conformational effects.

Treatment of the 3-*O*-methyl-2-*O*-tosyl ribo **25** or arabino **30** substrates produced the aromatized 2-(2-hydroxyethyl)-3-methoxyfuran (**37**) plus the respective 6-hydroxy-2-*O*-tosyl byproducts **38** or **39**. Generation of a carbonyl group at C3 is precluded with **25** and **30**, but a favorable six-membered transition state involving attraction between the α-proton on C1 and a tosylate oxygen with epimer **25** (Figure 5) might aid the loss of HOTs with generation of a 1,2-double bond. An analogous interaction involving the β-proton on C1 and a tosylate oxygen with arabino epimer **30** also is possible. Abstraction of hydrogen from C4 of the resulting resonance hybrid would produce furan **37**. The observed similar yields of **37** plus the respective 2-*O*-tosyl byproducts **38** and **39** are consistent with parallel processes for the ribo **25** and arabino **30** epimers. Tosylate **25** was stable in toluene at 95 °C, which confirmed that generation of a C3 radical was necessary for the elimination of tosylate and production of **37**.

**Figure 5.** TsOH elimination and aromatization.

## 4. Experimental Section

The $^1$H (400 or 500 MHz) and $^{13}$C (100 or 125 MHz) NMR spectra were determined on Bruker Biospin spectrometers (Bruker, Billerica, MA, USA) with solutions in CDCl$_3$ unless otherwise noted. HRMS were obtained in TOF-ESI mode on Bruker Solarix FT-ICR instrument (Bruker, Billerica, MA, USA) unless otherwise noted. TLC was performed with Merck (Darmstadt, Germany) kieselgel 60-F$_{254}$ sheets and products were detected with 254 nm light or by visualization with Ce(SO$_4$)$_2$/(NH$_4$)$_6$Mo$_7$O$_{24}$·4H$_2$O/H$_2$SO$_4$/H$_2$O reagent. Merck kieselgel 60 (230–400 mesh) was used for column chromatography. Reagent grade chemicals were used, and solvents were dried by reflux over and distillation from CaH$_2$ (except for THF/potassium) under argon or by passing the solvents through activated alumina cartridges using a solvent purification system.

**Methyl 6-*O*-Benzoyl-1,5-dideoxy-2,3-*O*-isopropylidene-β-D-*ribo*-hexofuranoside (2).** To a solution of methyl 1,5-dideoxy-2,3-isopropylidene-β-D-*ribo*-hexofuranoside [29] (**1**; 13.0 g, 58.8 mmol) and Et$_3$N (8.9 g, 12.3 mL, 88.2 mol) in CH$_2$Cl$_2$ (50 mL) was added dropwise BzCl (12.4 g, 10.2 mL, 88.2 mmol) at 0 °C. The cooling bath was removed and after 1 h the reaction mixture was quenched by addition of MeOH (2 mL). After additional 30 min the volatiles were evaporated and the residue was column chromatographed (hexanes → hexanes/EtOAc, 6:1) to give **2** as pale yellow oil (17.3 g, 92%): $^1$H NMR δ 1.32, 1.49 (2 × s, 2 × 3H), 2.01–2.04 (m, 2H), 3.38 (s, 3H), 4.39–4.52 (m, 3H), 4.62–4.65 (m, 2H), 4.98 (s, 1H), 7.42–7.57 (m, 3H), 8.04–8.06 (m, 2H); $^{13}$C NMR δ 24.6, 26.2, 33.9, 54.8, 61.6, 83.6, 84.0, 85.2, 109.6, 112.0, 128.1, 129.3, 129.9, 132.6, 166.0; MS FAB *m/z* 345 (3, [M + Na]$^+$), 291 (100, [M − OMe]$^+$); HRMS ESI *m/z* calcd for C$_{17}$H$_{22}$O$_6$Na [M + Na]$^+$ 345.1314, found 345.1317.

**6-*O*-Benzoyl-1,5-dideoxy-D-*ribo*-hexofuranose (3)** and **6-*O*-Benzoyl-1,5-dideoxy-2,3-*O*- isopropylidene-D-*ribo*-hexofuranose (4).** To a stirred solution of **2** (18.0 g, 55.9 mmol) and Et$_3$SiH (19.4 g, 26.7 mL, 167.7 mmol) in CH$_2$Cl$_2$ (10 mL) was added BF$_3$•OEt$_2$ (23.8 g, 21.3 mL, 167.7 mmol). Mildly exothermic reaction ensued after approx. 15 min and the reaction mixture was allowed to stir for an additional 3 h. The reaction flask was placed in an ice slush and a saturated NaHCO$_3$/H$_2$O solution (200 mL) was added slowly with vigorous stirring. CH$_2$Cl$_2$ was added (50 mL), aqueous phase was separated and washed with CH$_2$Cl$_2$ (50 mL). Organic fractions were combined and evaporated to dryness. Column chromatography (hexanes/EtOAc, 6:1 → EtOAc) gave contaminated (~10%) **4** (1.5 g, 9%) and **3** (6.1 g, 43%) as syrup. Compound **3** had: $^1$H NMR (CD$_3$OD) δ 1.87–1.94 (m, 1H), 2.12–2.19 (m, 1H), 3.70 (dd, *J* = 2.9, 9.8 Hz, 1H), 3.79 (dd, *J* = 5.4, 7.3 Hz, 1H), 3.85–3.89 (m, 1H), 4.07 (dd, *J* = 4.9, 9.8 Hz, 1H), 4.16 (td, *J* = 2.9, 4.9 Hz, 1H), 4.38–4.50 (m, 2H), 7.45–7.61 (m, 3H), 8.02–8.04 (m, 2H); $^{13}$C NMR (CD$_3$OD) δ 32.4, 61.9, 70.8, 72.2, 75.9, 78.9, 128.3, 129.5, 129.9, 133.0, 166.8; MS FAB *m/z* 275 (100, [M + Na]$^+$); HRMS ESI *m/z* calcd for C$_{13}$H$_{16}$O$_5$Na [M + Na]$^+$ 275.1531, found 275.0902.

Diol **3** (6.1 g, 24.2 mmol) and TsOH hydrate (0.5 g, 2.6 mmol) were dissolved in a mixture of acetone (40 mL) and 2,2-dimethoxypropane (10 mL) and left to stir at room temperature for 30 min. Neutralization with sat. NaHCO$_3$ (100 mL) followed by EtOAc extraction (2 × 50 mL) and evaporation

to dryness provided oil that was filtered through silica to give **4** (6.4 g, 91%): $^1$H NMR δ 1.33, 1.52 (2 × s, 2 × 3H), 1.86–1.92 (m, 2H), 3.86 (dd, *J* = 4.4, 10.7 Hz, 1H), 3.97 (dd, *J* = 1.5, 10.7 Hz, 1H), 4.23–4.26 (m, 1H), 4.36–4.49 (m, 2H), 4.52 (dd, *J* = 1.5, 6.3 Hz, 1H), 4.80–4.83 (m, 1H), 7.42–7.57 (m, 3H), 8.03–8.05 (m, 2H); $^{13}$C NMR δ 24.9, 26.5, 29.7, 61.5, 71.6, 80.8, 81.2, 85.0, 112.8, 128.3, 129.5, 130.1, 132.9, 166.4. MS FAB *m/z* 293 (100, [M + H]$^+$), 315 (15, [M + Na]$^+$); HRMS ESI *m/z* calcd for $C_{16}H_{20}O_5Na$ [M + Na]$^+$ 315.1208, found 315.1209.

**1,5-Dideoxy-2,3-*O*-isopropylidene-D-*ribo*-hexofuranose (5).** To a stirred solution of **4** (14.0 g, 47.9 mmol) in MeOH (50 mL) was added a solution of KOH (2.0 g, 35.7 mol) in MeOH (50 mL). After 1 h the volatiles were evaporated and the residue was column chromatographed (hexanes/EtOAc, 2:1 → EtOAc) to give **5** [45] (8.0 g, 87%): $^1$H NMR δ 1.33, 1.51 (2 × s, 2 × 3H), 1.63–1.76 (m, 2H), 3.74–3.82 (m, 2H), 3.89 (dd, *J* = 4.4, 10.4 Hz, 1H), 3.94 (d, *J* = 10.3 Hz, 1H), 4.19–4.22 (m, 2H), 4.48 (dd, *J* = 1.5, 5.8 Hz, 1H), 4.81 (t, *J* = 5.1 Hz, 1H); $^{13}$C NMR δ 24.5, 26.2, 32.4, 59.2, 71.1, 80.4, 82.2, 84.6, 112.3. MS FAB *m/z* 189 (100, [M + H]$^+$); HRMS ESI *m/z* calcd for $C_9H_{17}O_4$ [M + H]$^+$ 189.1127, found 189.1123.

**6-Iodo-1,5,6-trideoxy-2,3-*O*-isopropylidene-D-*ribo*-hexofuranose (6).** To a stirred solution of **5** (9.0 g, 47.9 mmol), Ph$_3$P (15.1 g, 57.6 mmol) and imidazole (7.9 g, 116.2 mmol) in toluene (225 mL) was added iodine (14.6 g, 57.5 mmol) at 70 °C. The suspension was vigorously stirred another 2 h, then allowed to cool to ambient temperature and the solution decanted to another flask. Volatiles were evaporated and the residue was column chromatographed (hexanes → hexanes/EtOAc, 6:1) to give **6** (13.03 g, 85%): $^1$H NMR δ 1.33, 1.52 (2 × s, 2 × 3H), 1.88–1.97 (m, 2H), 3.14–3.27 (m, 2H), 3.78 (dd, *J* = 4.4, 10.7 Hz, 1H), 3.95 (dd, *J* = 1.5, 10.7 Hz, 1H), 4.10 (ddd, *J* = 1.5, 4.9, 9.2 Hz, 1H), 4.23 (dd, *J* = 2.0, 6.3 Hz, 1H), 4.78 (m, 1H); $^{13}$C NMR δ 1.0, 24.7, 26.2, 34.0, 71.2, 80.4, 83.6, 84.1, 112.3; MS FAB *m/z* 321 (12, [M + Na]$^+$), 319 (100); HRMS ESI *m/z* calcd for $C_9H_{15}IO_3Na$ [M + Na]$^+$ 320.9964, found 320.9970.

**6-Iodo-1,5,6-trideoxy-D-*ribo*-hexofuranose (7).** A solution of **6** (14.0 g, 47.0 mmol) in a mixture of MeOH (100 mL), H$_2$O (25 mL) and conc. HCl (25 mL) was stirred at room temperature for 3 h. Volatiles were evaporated and the residue was column chromatographed (hexanes/EtOAc, 2:1 → EtOAc) to give **7** (8.73 g, 72%): $^1$H NMR δ 2.00–2.07 (m, 1H), 2.16–2.25 (m, 1H), 3.22–3.45 (m, 4H), 3.74–3.77 (m, 2H), 3.84 (br s, 1H), 4.10 (dd, *J* = 4.9, 10.3 Hz, 1H), 4.27 (br s, 1H); $^{13}$C NMR δ 1.7, 37.3, 70.9, 72.8, 75.6, 81.6; MS FAB *m/z* 258 (10, [M]$^+$), 74 (100); HRMS ESI *m/z* calcd for $C_6H_{11}IO_3$, 257.9753, found 257.9740.

**1,5-Dideoxy-6-*O*-nitro-D-*ribo*-hexofuranose (8).** A suspension of **7** (12.0 g, 46.5 mmol) and AgNO$_3$ (15.8 g, 93.0 mmol) in CH$_3$CN (150 mL) was stirred at room temperature for 2 days. The yellow precipitate was filtered off, washed with EtOAc and the volatiles were evaporated. Column chromatography (hexanes/EtOAc, 1:1 → EtOAc) gave **8** (7.99 g, 89%): $^1$H NMR δ 1.88–1.96 (m, 1H), 2.08–2.15 (m, 1H), 3.43 (br s, 2H), 3.73–3.83 (m, 3H), 4.12 (dd, *J* = 4.9, 10.3 Hz, 1H), 4.23–4.26 (m, 1H), 4.56–4.66 (m, 2H); $^{13}$C NMR δ 30.2, 70.1, 70.8, 72.6, 75.9, 77.8; MS FAB *m/z* 216 (100, [M + Na]$^+$); HRMS ESI *m/z* calcd for $C_6H_{11}NO_6Na$ [M + Na]$^+$, 216.0484 found 216.0497.

**1,5-Dideoxy-6-*O*-nitro-2-*O*-tosyl-D-*ribo*-hexofuranose (9). Method A.** A solution of diol **8** (370 mg, 1.92 mmol) and Bu$_2$SnO (477 mg, 1.92 mmol) in anhydrous MeOH (40 mL) was heated in a sealed flask at 75 °C for 1 h. After the flask was cooled to 0 °C, Et$_3$N (1.15 g, 1.6 mL, 11.4 mmol) was added with stirring followed by TsCl (2.17 g, 11.4 mmol) dissolved in a minimum volume of acetone. The volatiles were evaporated, and the residue was suspended in acetone and deposited on silica. Column chromatography (hexanes/EtOAc, 6:1 → 3:1) gave a 5:2 mixture of two isomers (670 mg) from which the main product **9** (320 mg, 48%) was isolated after second column chromatography: $^1$H NMR δ 1.85–1.92 (m, 1H), 2.09–2.17 (m, 1H), 2.46 (s, 3H), 2.76 (d, *J* = 7.8 Hz, 1H), 3.75 (dt, *J* = 3.9, 8.3 Hz, 1H), 3.80 (dd, *J* = 3.1, 11.2 Hz, 1H), 3.89 (dt, *J* = 5.4, 7.8 Hz, 1H), 4.06 (dd, *J* = 4.9, 11.2 Hz, 1H), 4.52–4.62 (m, 2H), 4.93 (dt, *J* = 3.0, 5.3 Hz, 1H), 7.38, 7.82 (2 × d, *J* = 8.3 Hz, 2 × 2H); $^{13}$C NMR δ 21.6, 30.2, 69.8, 70.1, 74.9, 77.8, 79.4, 127.8, 130.1, 132.8, 145.6; MS FAB *m/z* 370 (100, [M + Na]$^+$); HRMS ESI *m/z* calcd for $C_{13}H_{17}NO_8SNa$ [M + Na]$^+$ 370.0573, found 370.0587.

**Method B.** Step a: TsCl (66 mg, 0.35 mmol) was added to a stirred solution of **10** (100 mg, 0.32 mmol) in anhydrous pyridine (1 mL) at ambient temperature. After 16 h, the volatiles were evaporated and residue was partitioned between ice-cold AcOH/H$_2$O (1:99, 30 mL) and CHCl$_3$ (30 mL). The aqueous layer was extracted with CHCl$_3$ and the combined organic phase was washed with ice-cold saturated NaHCO$_3$/H$_2$O (30 mL), brine (30 mL) and dried (Na$_2$SO$_4$). Column chromatography (EtOAc/hexane, 5:95 → 35:65) gave 1,5-dideoxy-3-*O*-(*p*-methoxybenzyl)- 6-*O*-nitro-2-*O*-tosyl-D-*ribo*-hexofuranose (**15**; 82 mg, 55%): $^1$H NMR δ 1.78–1.81 (m, 1H), 2.00–2.02 (m, 1H), 2.47 (s, 3H), 3.59 (dd, *J* = 5.0, 8.6 Hz, 1H), 3.83 (s, 3H), 3.86 (dt, *J* = 2.2, 9.6 Hz, 2H), 4.04 (dd, *J* = 4.5, 11.2 Hz, 2H), 4.26 (d, *J* = 11.2 Hz, 1H), 4.47 (m, 2H), 4.58 (d, *J* = 11.2 Hz, 1H), 5.13 (dt, *J* = 4.7, 7.0 Hz, 1H), 6.88 and 7.21 (2 × d, *J* = 9.5 Hz, 2 × 2H), 7.34 and 7.84 (2 × d, *J* = 8.3 Hz, 2 × 2H). In step b, A solution of CAN (176 mg, 0.32 mmol) and **15** (75 mg, 0.16 mmol) in MeCN (1.5 mL) and water (0.15 mL) was stirred at ambient temperature for 22 h. Volatiles were evaporated and the residue was column chromatographed (EtOAc/hexane, 3:97 → 30:70) to give **9** (54 mg, 98%) with data as above.

**1,5-Dideoxy-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*ribo*-hexofuranose (10).** A suspension of diol **8** (1.20 g, 6.22 mmol) and Bu$_2$SnO (1.70 g, 6.84 mmol) in anhydrous MeOH (10 mL) was heated in a sealed flask at 75 °C for 1 h. After the flask was cooled to ambient temperature, the volatiles were evaporated. DMF (5 mL) and PMBCl (1.95 g, 1.7 mL, 12.44) were added, and the reaction mixture was heated at 90 °C for 18 h. Volatiles were evaporated, and the residue was chromatographed (hexanes/EtOAc, 6:1 → 1:1) to give 1,5-dideoxy-2,3-di-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*ribo*- hexofuranose (1.55 g; 20% contaminated) followed by 1,5-dideoxy-2-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*ribo*-hexofuranose (0.47 g, 24%) and **10** (0.60 g; 31%) of sufficient purity for use in subsequent reaction. Sample of **10** was repurified on column chromatography for spectroscopic characterization: $^1$H NMR δ 1.77–1.85 (m, 1H), 1.93–2.00 (m, 1H), 3.20 (br s, 1H), 3.60 (dd, *J* = 5.4, 7.3 Hz, 1H), 3.76 (dd, *J* = 2.9, 10.3 Hz, 1H), 3.81 (s, 3H), 3.85 (dt, *J* = 3.9, 7.3 Hz, 1H), 4.01 (dd, *J* = 4.9, 10.3 Hz, 1H), 4.18 (m, 1H), 4.47–4.61 (m, 4H), 6.88–6.92 (m, 2H), 7.24–7.30 (m, 2H); $^{13}$C NMR δ 30.5, 55.2, 69.1, 70.0, 72.6, 73.3, 76.1, 82.4, 114.0, 128.8, 129.7, 159.7; MS FAB *m/z* 336 (100, [M + Na]$^+$); HRMS ESI *m/z* calcd for C$_{14}$H$_{19}$NO$_7$Na [M + Na]$^+$ 336.1059, found 336.1072.

**2-Chloro-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-1,2,5-trideoxy-D-*arabino*-hexofuranose (11).** To a solution of Ph$_3$P (2.18 g, 8.31 mmol) and DIAD (1.26 g, 1.22 mL, 6.23 mmol) in THF (14 mL) was added a solution of **10** (0.65 g, 2.08 mmol) in THF (6 mL) followed by freshly prepared HCl•pyridine (0.72 g, 6.23 mmol; prepared by slow addition of TMSCl (0.68 g, 0.8 mL, 6.31 mmol) to a solution of pyridine (0.98 g, 1.0 mL, 12.4 mmol) in MeOH (0.32 g, 0.4 mL, 9.9 mmol) and CH$_2$Cl$_2$ (10 mL) at 0 °C. Volatiles were evaporated and the crystalline residue was dried at 80 °C under vacuum overnight). The suspension was stirred overnight at room temperature. Volatiles were evaporated, and the residue was column chromatographed (hexanes/EtOAc, 10:1 → 6:1) to give **11** (0.43 g, 62%): $^1$H NMR δ 2.05–2.10 (m, 2H), 3.82 (br s, 4H), 3.81–3.86 (m, 1H), 3.90 (br d, *J* = 3.4 Hz, 1H), 4.02 (d, *J* = 10.3 Hz, 1H), 4.13 (dd, *J* = 4.4, 10.7 Hz, 1H), 4.47–4.65 (m, 4H), 6.90–6.93 (m, 2H), 7.25–7.28 (m, 2H); $^{13}$C NMR δ 30.9, 55.2, 60.1, 70.0, 72.1, 74.2, 80.9, 89.8, 113.9, 128.8, 129.6, 159.5; HRMS ESI *m/z* Calcd for C$_{14}$H$_{18}$ClNO$_6$Na [M + Na]$^+$ 354.0720, found 354.0706.

**2-Chloro-1,2,5-trideoxy-6-*O*-nitro-D-*arabino*-hexofuranose (13).** A solution of **11** (0.43 g, 1.30 mmol) and CAN (1.42 g, 2.59 mmol) in CH$_3$CN (7 mL) and H$_2$O (0.7 mL) was stirred for 1.5 h. The reaction mixture was concentrated, and the residue was deposited on silica gel and column chromatographed (hexanes/EtOAc, 10:1 → 3:1) to give **13** (0.21 g, 78%): $^1$H NMR δ 2.10–2.22 (m, 2H), 2.69 (br s, 1H), 3.80–3.84 (m, 1H), 4.02 (br d, *J* = 10.8 Hz, 1H), 4.14–4.25 (m, 3H), 4.58–4.68 (m, 2H); $^{13}$C NMR δ 30.9, 62.3, 70.0, 73.3, 81.7, 83.2; MS FAB *m/z* 212 (5, [M + H]$^+$), 120 (100); HRMS ESI *m/z* calcd for C$_6$H$_{11}$ClNO$_5$ [M + H]$^+$ 212.0326, found 212.0327.

**2-Bromo-1,2,5-trideoxy-6-*O*-nitro-D-*arabino*-hexofuranose (14).** Step a: To a solution of Ph$_3$P (2.85 g, 10.09 mmol) and DIAD (1.65 g, 8.15 mmol) in THF (30 mL) was added a stirred solution of **10** (1.75 g,

5.43 mmol) in THF (10 mL) followed by freshly prepared HBr•pyridine (1.30 g, 8.15 mmol; prepared by slow addition of TMSBr (0.93 g, 0.8 mL, 6.06 mmol) to a solution of pyridine (0.98 g, 1.0 mL, 12.4 mmol) in MeOH (0.32 g, 0.4 mL, 9.9 mmol) and $CH_2Cl_2$ (10 mL) at 0 °C. Volatiles were evaporated and the crystalline residue was dried at 80 °C under vacuum overnight). The suspension was stirred at room temperature for 22 h. Volatiles were evaporated, and the residue was column chromatographed (hexanes/EtOAc, 10:1 → 6:1) to give crude 2-bromo-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-1,2,5-trideoxy-D-arabino-hexofuranose (**12**; 1.0 g, 49%) which was directly used in next step. Step b. A solution of crude **12** (1.0 g, 2.66 mmol) and CAN (2.91 g, 5.32 mmol) in a mixture of $CH_3CN$ (14 mL) and $H_2O$ (1.4 mL) was stirred for 1.5 h. The resulting mixture was concentrated and the residue was deposited on silica and column chromatographed (hexanes/EtOAc, 10:1 → 4:1) to give **14** (0.54 g, 79%): ^{1}H NMR δ 2.14–2.26 (m, 2H), 3.80–3.86 (dt, *J* = 5.2, 8.8 Hz, 1H), 4.10 (dd, *J* = 4.0, 10.6 Hz, 1H), 4.16–4.22 (m, 1H), 4.26–4.33 (m, 2H), 4.58–4.72 (m, 2H); ^{13}C NMR δ 31.2, 51.5, 69.9, 73.6, 81.5, 83.5. HRMS ESI/DART *m/z* calcd for $C_6H_{14}{}^{79}BrN_2O_5$ [M + NH$_4$]$^+$ 273.0081, found 273.0084; calcd for $C_6H_{14}{}^{81}BrN_2O_5$ [M + NH$_4$]$^+$ 275.0061, found 275.0061.

**1,5-Dideoxy-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*arabino*-hexofuranose (16b)**. Step a: A solution of compound **10** (2.70 g, 8.63 mmol) in THF (8 mL) followed by a solution of DIAD (2.09 g, 2.03 mL, 10.35 mmol) in THF (3 mL) were slowly (12 min) added to a stirred solution of Ph$_3$P (2.71 g, 10.35 mmol) and PhCO$_2$H (1.26 g, 10.35 mmol) in THF (40 mL) at –50 °C under nitrogen atmosphere. The resulting mixture was allowed to warm to ambient temperature within 1 h (it became colorless at –20 °C). Volatiles were evaporated, and the residue was column chromatographed (hexanes → hexanes/EtOAc, 3:1) to give 2-*O*-benzoyl-1,5-dideoxy-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*arabino*-hexofuranose (**16a**; 2.87 g, 80%): ^{1}H NMR δ 2.0–2.07 (m, 2H), 3.79 (s, 3H), 3.85 (td, *J* = 1.0, 4.6 Hz, 1H), 3.90 (td, *J* = 5.0, 7.6 Hz, 1H), 4.08–4.12 (m, 2H), 4.51–4.59 (m, 3H), 4.75 (d, *J* = 11.7 Hz, 1H), 5.43 (td, *J* = 1.4, 2.7 Hz, 1H), 6.86 (d, *J* = 8.7 Hz, 2H), 7.27 (d, *J* = 8.7, 2H), 7.47 (t, *J* = 7.7 Hz, 2H), 7.61 (tt, *J* = 1.5, 7.5 Hz, 1H), 8.03 (d, *J* = 7.6 Hz, 2H). Step b: A suspension of KOH (0.40 g, 7.14 mol) in MeOH (20 mL) was added to a stirred solution of **16a** (2.82 g, 6.76 mmol) in MeOH (20 mL) at ambient temperature. After 1 h, the solution was neutralized with AcOH to pH 7. The volatiles were evaporated and the residue was column chromatographed (hexanes/EtOAc, 3:1 → 2:1) to give **16b** (1.64 g, 77%): ^{1}H NMR δ 1.26 (d, *J* = 2.9 Hz, 1H), 2.00–2.04 (m, 2H), 3.64 (d, *J* = 2.9 Hz, 1H), 3.80 (br s, 4H), 3.83 (d, *J* = 10.3 Hz, 1H), 3.91 (dd, *J* = 3.9, 10.3 Hz, 1H), 4.27–4.29 (m, 1H), 4.48–4.58 (m, 4H), 6.88–6.91 (m, 2H), 7.24–7.27 (m, 2H); ^{13}C NMR δ 30.9, 55.2, 70.2, 71.8, 74.1, 76.1 80.3, 89.2, 113.9, 128.4, 129.5, 159.4; MS FAB *m/z* 336 (100, [M + Na]$^+$); HRMS ESI *m/z* calcd for $C_{14}H_{19}NO_7Na$ [M + Na]$^+$ 336.1059, found 336.1047.

**1,5-Dideoxy-6-*O*-nitro-2-*O*-tosyl-D-*arabino*-hexofuranose (18)**. Step a: TsCl (134 mg, 0.70 mmol) was added to a stirred solution of **16b** (100 mg, 0.32 mmol) in anhydrous pyridine (1mL) at ambient temperature. After 16 h, the volatiles were evaporated and residue was partitioned between ice-cold AcOH/$H_2O$ (1:99, 30 mL) and CHCl$_3$ (30 mL). The organic layer was separated, and the aqueous layer was extracted with CHCl$_3$ (30 mL). Combined organic phase was washed with ice-cold saturated NaHCO$_3$/$H_2O$ (30 mL), brine (30 mL) and dried (Na$_2$SO$_4$), concentrated in vacuo and column chromatographed (EtOAc/hexane, 5:95 → 35:65) to give 1,5-dideoxy-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-2-*O*-tosyl-D-*arabino*-hexofuranose (**17a**; 128 mg, 86%) as a colorless oil: ^{1}H NMR δ 1.90–1.96 (m, 2H), 2.46 (s, 3H), 3.72–3.78 (m, 1H), 3.82 (s, 3H), 3.84 (dt, *J* = 1.2, 4.6 Hz, 1H), 3.87 (d, *J* = 4.0 Hz, 1H), 3.92 (d, *J* = 11.3 Hz, 1H), 4.33 (d, *J* = 11.3 Hz, 1H), 4.42–4.49 (m, 3H), 4.93 (dt, *J* = 1.2, 4.0 Hz, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 7.16 (d, *J* = 8.7 Hz, 2H), 7.38 (d, *J* = 8.2 Hz, 2H), 7.81 (d, *J* = 8.2 Hz, 2H); ^{13}C NMR δ 21.6, 30.3, 55.3, 69.8, 71.4, 71.8, 80.2, 83.9, 86.3, 114.0, 127.8, 128.8, 129.5, 130.1, 133.4, 145.4, 159.6. Step b: A solution of CAN (352 mg, 0.64 mmol) and **17a** (100 mg, 0.21 mmol) in MeCN (1 mL) and $H_2O$ (0.1 mL) was stirred at ambient temperature for 22 h. Volatiles were evaporated and the residue was column chromatographed (EtOAc/hexane, 3:97 → 30:70) to give **18** (73 mg, 98%) as a colorless oil: ^{1}H NMR δ 1.97–2.07 (m, 1H), 2.07–2.17 (m, 1H), 2.47 (s, 3H), 3.69–3.76 (m, 1H), 3.85–3.90 (m, 1H), 3.95 (dd, *J* = 5.5, 11.3 Hz, 1H), 4.17 (dd, *J* = 2.5, 6.0 Hz, 1H), 4.51–4.63 (m, 2H), 4.76 (dt, *J* = 2.5, 5.5 Hz, 1H), 7.38 (d, *J* = 8.5 Hz, 2H), 7.80 (d, *J* = 8.5 Hz, 2H); ^{13}C NMR δ 21.6,

30.2, 69.7, 70.3, 80.5, 80.9, 86.5, 127.9, 130.1, 132.8, 145.6. HRMS ESI/DART *m/z* calcd for $C_{13}H_{21}N_2O_8S$ $[M + NH_4]^+$ 365.1013, found 365.1031.

**2-Chloro-1,2,5-trideoxy-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*ribo*-hexofuranose (19)**. Step a: TfCl (160 mg, 0.95 mmol) was added to a stirred solution of **16b** (250 mg, 0.80 mmol) and DMAP (295 mg, 2.4 mmol) in anhydrous $CH_2Cl_2$ (2 mL) at 0 °C (ice-bath). After 1 h, the reaction mixture was partitioned between ice-cold $AcOH/H_2O$ (1:99, 30 mL) and $CH_2Cl_2$ (30 mL). The aqueous layer was extracted with $CH_2Cl_2$ (30 mL) and the combined organic phase was washed with ice-cold saturated $NaHCO_3/H_2O$ (30 mL), brine (30 mL) and dried ($Na_2SO_4$) to give 1,5-dideoxy-3-*O*-(*p*-methoxybenzyl)-2-*O*-(trifluoromethanesulfonyl)-6-*O*-nitro-D-*arabino*-hexofuraose as a colorless oil (**17b**; 313 mg, 88%) of sufficient purity to be used in next step. Column chromatography (EtOAc/hexane, 5:95 → 30:70) gave pure sample of **17b**: $^1$H NMR δ 1.93–2.02 (m, 2H), 3.80–3.84 (m, 1H), 3.82 (s, 3H), 3.92 (dt, *J* = 1.2, 4.6 Hz, 1H), 4.02 (dd, *J* = 3.5, 12.0 Hz, 1H), 4.18 (br d, *J* = 12.1 Hz, 1H), 4.47–4.52 (m, 3H), 4.66 (d, *J* = 11.5 Hz, 1H), 5.32 (d, *J* = 3.5 Hz, 1H), 6.91 (d, *J* = 8.8 Hz, 2H), 7.24 (d, *J* = 8.8 Hz, 2H). Step b: A solution of crude **17b** (50 mg, 0.11 mmol; from Step a) and dried LiCl (23 mg, 0.54 mmol) in DMF (1 mL) was stirred for 5 h at ambient temperature under $N_2$. Volatiles were evaporated and residue was partitioned between ice-cold saturated $NaHCO_3/H_2O$ (15 mL) and EtOAc (15 mL). The separated organic phase was washed with brine (30 mL), dried ($Na_2SO_4$) and column chromatographed (EtOAc/hexane, 5:95 → 15:85) to give **19** (30 mg, 80.6%) as a colorless oil: $^1$H NMR δ 1.82–1.91 (m, 1H), 2.01–2.1 (m, 1H), 3.72 (dd, *J* = 5.2, 8.2 Hz, 1H), 3.82 (s, 3H), 3.99 (dt, *J* = 4.0, 8.2 Hz, 1H), 4.06 (dd, *J* = 2.8, 10.7 Hz, 1H), 4.30 (dd, *J* = 5.07,10.7 Hz, 1H), 4.40 (d, *J* = 11.2 Hz, 1H), 4.44 (dt, *J* = 2.2, 5.2 Hz, 2H), 4.48–4.59 (m, 2H), 4.69 (d, 11.3 Hz, 1H), 6.90 (d, *J* = 8.7 Hz, 2H), 7.30 (d, *J* = 8.7 Hz, 2H); $^{13}$C NMR δ 30.4, 55.2, 57.8, 69.9, 72.1, 74.0, 76.3, 81.5, 114.0, 128.8, 129.8, 159.7. HRMS ESI *m/z* calcd for $C_{14}H_{18}{}^{35}ClNO_6Na$ $[M + Na]^+$ 354.0715, found 354.0718; calcd for $C_{14}H_{18}{}^{37}ClNO_6Na$ $[M + Na]^+$ 356.0691, found 356.0694.

**2-Chloro-1,2,5-trideoxy-6-*O*-nitro-D-*ribo*-hexofuranose (20)**. A solution of CAN (74 mg, 0.13 mmol) and **19** (15 mg, 0.04 mmol) in MeCN (1mL) and $H_2O$ (0.1 mL) was stirred at ambient temperature for 22 h. Volatiles were evaporated and the residue was column chromatographed (EtOAc/hexane, 3:97 → 30:70) to give **20** (6.2 mg, 66%) as a colorless oil: $^1$H NMR δ 1.87–1.98 (m, 1H), 2.11–2.20 (m, 1H), 2.25 (d, *J* = 8.7 Hz, 1H), 3.82–3.88 (m, 1H), 3.93–4.00 (m, 1H), 4.02 (dd, *J* = 4.0, 10.7 Hz, 1H), 4.33 (dd, *J* = 5.4, 10.5 Hz, 1H), 4.44–4.48 (m, *J* = 4.2, 5.3 Hz, 1H), 4.55–4.67 (m, 2H); $^{13}$C NMR δ 30.5, 61.1, 69.8, 72.9, 75.7, 78.3; HRMS ESI/DART *m/z* calcd for $C_6H_{14}{}^{35}ClN_2O_5$ $[M + NH_4]^+$ 229.0586, found 229.0588; calcd for $C_6H_{14}{}^{37}ClN_2O_5$ $[M + NH_4]^+$ 231.0562, found 231.0561.

**2-Bromo-1,2,5-trideoxy-3-*O*-(*p*-methoxybenzyl)-6-*O*-nitro-D-*ribo*-hexofuranose (21)**. A solution of **17b** (30 mg, 0.06 mmol; prepared as described for **19**, Step a) and dried LiBr (29 mg, 0.33 mmol) in DMF (1 mL) was stirred for 7 h at ambient temperature under $N_2$. Volatiles were evaporated and the resulting residue was partitioned between ice-cold saturated $NaHCO_3/H_2O$ (15 mL) and EtOAc (15 mL). The separated organic phase was washed with brine (30 mL), dried ($Na_2SO_4$) and column chromatographed (EtOAc/hexane, 5:95 → 15:85) to give **21** (18 mg, 71%) as a colorless oil: $^1$H NMR δ 1.83–1.94 (m, 1H), 2.02–2.12 (m, 1H), 3.6 (dd, *J* = 5.0, 7.6 Hz, 1H), 3.84 (s, 3H), 4.03 (dt, *J* = 4.0, 8.0 Hz, 1H), 4.22 (dd, *J* = 2.8, 10.6 Hz, 1H), 4.44 (d, *J* = 11.1 Hz, 1H), 4.43–4.51 (m, 2 H), 4.51–4.61 (m, 2H), 4.71 (d, *J* = 11.1 Hz, 1H) 6.92 (d, *J* = 8.6 Hz, 2H), 7.33 (d, *J* = 8.6 Hz, 2H); $^{13}$C NMR δ 30.4, 49.7, 55.3, 69.9, 72.1, 74.1, 76.6, 81.2, 114.0, 128.81, 129.8, 159.71. HRMS ESI *m/z* calcd for $C_{14}H_{18}{}^{79}BrNO_6Na$ $[M + Na]^+$ 398.0210, found 398.0203; calcd for $C_{14}H_{18}{}^{81}BrNO_6Na$ $[M + Na]^+$ 400.0191, found 400.0183.

**2-Bromo-1,2,5-trideoxy-6-*O*-nitro-D-*ribo*-hexofuranose (22)**. A solution of CAN (78 mg, 0.14 mmol) and **21** (18 mg, 0.05 mmol) in MeCN (1 mL) and water (0.1 mL) was stirred at ambient temperature for 22 h. Volatiles were evaporated and the residue was column chromatographed (EtOAc/hexane, 3:97 → 30:70) to give **22** (12 mg, 96%) as a colorless oil: $^1$H NMR δ 1.89–1.98 (m, 1H), 2.11–2.20 (m, 2H), 3.78–3.84 (m, 1H), 3.85–3.92 (m, 1H), 4.13 (dd, *J* = 4.6 Hz, 1H), 4.43 (dd, *J* = 5.4 Hz, 1H), 4.48

(dd, *J* = 5.0 Hz, 1H), 4.55–4.70 (m, 2H); $^{13}$C NMR δ 31.6, 53.7, 69.8, 72.9, 75.3, 78.8. HRMS ESI/DART *m/z* calcd for $C_6H_{14}{}^{79}BrN_2O_5$ [M + NH$_4$]$^+$ 273.0081, found 273.0077; calcd for $C_6H_{14}{}^{81}BrN_2O_5$ [M + NH$_4$]$^+$ 275.0066, found 275.0058.

**1,5-Dideoxy-3-*O*-methyl-6-*O*-nitro-D-*ribo*-hexofuranose (23)** and **1,5-Dideoxy-2-*O*-methyl-6-*O*-nitro-D-*ribo*-hexofuranose (24)** and: A suspension of **8** (0.34 g, 1.76 mmol) and Bu$_2$SnO (0.44 g, 1.76 mmol) in anhydrous MeOH (8 mL) was refluxed for 30 min. Volatiles were evaporated after the flask was cooled to ambient temperature. DMF (1 mL) and MeI (1.14 g, 0.5 mL, 8.03 mmol) were added, the flask was sealed and the solution was stirred at 40 °C for 12 h. Volatiles were evaporated and the residue was column chromatographed (hexanes/EtOAc, 4:1 → 1:1) to give **23** (145 mg, 38%) and **24** (134 mg, 35%). Compound **23** had: $^1$H NMR δ 1.85–1.92 (m, 1H), 2.09–2.16 (m, 1H), 2.79 (d, *J* = 8.8 Hz, 1H), 3.44 (s, 3H), 3.67 (ddd, *J* = 3.9, 7.8, 8.8 Hz, 1H), 3.74–3.84 (m, 3H), 4.06 (dd, *J* = 4.4, 5.4 Hz, 1H), 4.56–4.65 (m, 2H); $^{13}$C NMR δ 30.5, 57.7, 70.0, 70.1, 75.4, 78.6, 79.4; MS FAB *m/z* 230 (100, [M + Na]$^+$); HRMS ESI *m/z* calcd for $C_7H_{13}NO_6Na$ [M + Na]$^+$ 230.0641, found 230.0651. Compound **24** had: $^1$H NMR δ 1.89–1.96 (m, 1H), 2.04–2.11 (m, 1H), 2.70 (d, *J* = 3.9 Hz, 1H), 3.45 (dd, *J* = 4.9, 6.8 Hz, 1H), 3.47 (s, 3H), 3.79 (dd, *J* = 2.9, 9.8 Hz, 1H), 3.86 (ddd, *J* = 3.9, 6.8, 8.3 Hz, 1H), 3.79 (dd, *J* = 4.4, 10.2 Hz, 1H), 4.31 (m, 1H), 4.55–4.65 (m, 2H); $^{13}$C NMR δ 30.8, 58.3, 68.9, 70.0, 73.2, 75.9, 85.2; MS FAB *m/z* 208 (100, [M + H]$^+$); HRMS ESI *m/z* calcd for $C_7H_{14}NO_6$ [M + H]$^+$ 208.0821, found 208.0819.

**1,5-Dideoxy-2-*O*-tosyl-3-*O*-methyl-6-*O*-nitro-D-*ribo*-hexofuranose (25).** TsCl (101 mg, 0.53 mmol) was added to a stirred solution of **23** (100 mg, 0.48 mmol) in anhydrous pyridine (1 mL) at ambient temperature. After 16 h, the volatiles were evaporated and residue was partitioned between ice-cold AcOH/H$_2$O (1:99, 30 mL) and CHCl$_3$ (30 mL). The organic layer was separated, and the aqueous layer was extracted with CHCl$_3$ (30 mL). Combined organic phase was washed with ice-cold NaHCO$_3$/H$_2$O (30 mL), brine (30 mL), dried (Na$_2$SO$_4$), concentrated in vacuo and column chromatographed (EtOAc/hexane, 5:95 → 35:65) to give **25** (110 mg, 63%) as a colorless oil: $^1$H NMR δ 1.86–1.96 (m, 1H), 2.05–2.15 (m, 1H), 2.48 (s, 3H), 3.31 (s, 3H), 3.47 (dd, *J* = 5.0, 8.6 Hz, 1H), 3.85 (dd, *J* = 4.2, 8.6 Hz, 1H), 3.89 (dd, *J* = 2.44, 11.5 Hz, 1H), 4.07 (dd, *J* = 4.44, 11.5 Hz, 1H), 4.51–4.63 (m, 2H), 5.12 (dt, *J* = 2.2, 4.7 Hz, 1H), 7.39 (d, *J* = 8.15 Hz, 2H), 7.85 (d, *J* = 8.15 Hz, 2H); $^{13}$C NMR δ 21.6, 30.5, 58.3, 69.8, 70.9, 75.9, 76.7, 83.7, 127.8, 129.9, 133.7, 145.2; HRMS ESI/DART *m/z* calcd for $C_{14}H_{23}N_2O_8S$ [M + NH$_4$]$^+$ 379.1170, found 379.1172.

**2-*O*-Benzoyl-1,5-dideoxy-3-*O*-methyl-6-*O*-nitro-D-*arabino*-hexofuranose (26).** Compound **23** (0.20 g, 0.97 mmol) in THF (6 mL) was added to a stirred solution of Ph$_3$P (0.31 g, 1.16 mmol) and PhCO$_2$H (0.14 g, 1.16 mmol) in THF (5 mL) at −50 °C. After 5 min. DIAD (0.23 g, 0.22 mL, 1.16 mmol) in THF (2 mL) was added slowly over 12 min. The reaction mixture was allowed to warm to room temperature within 1 h (it became colorless at −20 °C). Volatiles were evaporated, and the residue was column chromatographed (hexanes → hexanes/EtOAc, 10:1) to give **26** (0.23 g, 76%): $^1$H NMR δ 2.07–2.17 (m, 2H), 3.50 (s, 3H), 3.71 (d, *J* = 3.4 Hz, 1H), 3.86–3.90 (m, 1H), 4.03–4.07 (m, 2H), 4.57–4.66 (m, 2H), 5.38–5.40 (m, 1H), 7.44–7.62 (m, 3H), 8.02–8.14 (m, 2H); $^{13}$C NMR δ 30.8, 58.0, 70.0, 71.7, 77.9, 80.4, 89.6, 128.4, 129.4, 130.1, 133.4, 165.7; MS FAB *m/z* 334 (15, [M + Na]$^+$), 312 (100, [M + H]$^+$); HRMS ESI *m/z* calcd for $C_{14}H_{17}O_7NNa$ [M + Na]$^+$ 334.0903, found 334.0904.

**1,5-Dideoxy-3-*O*-methyl-6-*O*-nitro-D-*arabino*-hexofuranose (27).** KOH (1.62 g, 28.9 mmol) in MeOH (80 mL) was added to a stirred solution of **26** (1.82 g, 5.85 mmol) in MeOH (80 mL). The reaction mixture was left to stir at room temperature for 1 h, then was neutralized with 5% HCl/H$_2$O. Volatiles were evaporated, and the residue was column chromatographed (hexanes/EtOAc, 3:1 → 1:1) to give **27** (0.87 g, 72%): $^1$H NMR (300 MHz) δ 2.07–2.14 (m, 2H), 2.80 (br s, 1H), 3.42 (s, 3H), 3.48 (td, *J* = 1.1, 3.9 Hz, 1H), 3.79 (ddd, *J* = 3.9, 6.1, 7.3 Hz, 1H), 3.85 (br d, *J* = 10.3 Hz, 1H), 3.90 (dd, *J* = 3.7, 10.3 Hz, 1H), 4.27–4.29 (m, 1H), 4.54–4.67 (m, 2H); $^{13}$C NMR δ 30.9, 57.5, 70.2, 73.9, 75.2, 80.2, 91.6; MS FAB *m/z* 208 (5, [M + H]$^+$), 71 (100); HRMS ESI *m/z* calcd for $C_7H_{14}NO_6$ [M + H]$^+$ 208.0821, found 208.0807.

**2-Chloro-3-*O*-methyl-6-*O*-nitro-1,2,5-trideoxy-D-*arabino*-hexofuranose (28).** Solution of **23** (0.60 g, 2.90 mmol) in THF (15 mL) was added to a stirred solution of Ph$_3$P (1.52 g, 5.78 mmol) and DIAD (0.89 g, 0.86 mL, 4.38 mmol) in THF (15 mL) followed by addition of freshly prepared HCl•pyridine (0.50 g, 4.33 mmol). The suspension was stirred overnight at room temperature. Volatiles were evaporated, and the residue was chromatographed (hexanes → hexanes/EtOAc, 6:1) to give **28** (0.38 g, 61%): $^1$H NMR δ 2.14–2.18 (m, 2H), 3.44 (s, 3H), 3.73 (d, *J* = 3.9 Hz, 1H), 3.78–3.82 (m, 1H), 4.02 (d, *J* = 10.7 Hz, 1H), 4.10 (dd, *J* = 4.4, 10.7 Hz, 1H), 4.24–4.27 (m, 1H), 4.56–4.67 (m, 2H); $^{13}$C NMR δ 31.3, 58.1, 59.4, 70.0, 74.2, 80.9, 92.8; HRMS ESI/DART *m/z* calcd for C$_7$H$_{16}$$^{35}$ClN$_2$O$_5$ [M + NH$_4$]$^+$ 243.0742, found 243.0752; calcd for C$_7$H$_{16}$$^{37}$ClN$_2$O$_5$ [M + NH$_4$]$^+$ 245.0716, found 245.0715.

**2-Bromo-3-*O*-methyl-6-*O*-nitro-1,2,5-trideoxy-D-*arabino*-hexofuranose (29).** Solution of **23** (0.65 g, 3.13 mmol) in THF (15 mL) was added to a stirred solution of Ph$_3$P (1.64 g, 6.25 mmol) and DIAD (0.95 g, 0.92 mL, 4.69 mmol) in THF (15 mL) followed by addition of freshly prepared HBr•pyridine (0.75 g, 4.69 mmol). The suspension was stirred overnight at room temperature. Volatiles were evaporated, and the residue was column chromatographed (hexanes/EtOAc, 10:1 → 6:1) to give **29** (0.39 g, 46%): $^1$H NMR δ 2.19–2.27 (m, 2H), 3.49 (s, 3H), 3.82 (dt, *J* = 4.2, 6.8 Hz, 1H), 3.92 (d, *J* = 3.8 Hz, 1H), 4.14 (dd, *J* = 1.86, 11.0 Hz, 1H), 4.21 (dd, *J* = 4.47, 11.0 Hz, 1H), 4.27–4.31 (m, 1H), 4.58–4.70 (m, 2H); $^{13}$C NMR δ 31.5, 48.5, 58.0, 70.0, 74.6, 81.2, 93.0; HRMS ESI/DART *m/z* calcd for C$_7$H$_{16}$$^{79}$BrN$_2$O$_5$ [M + NH$_4$]$^+$ 287.0237, found 287.0252; calcd for C$_7$H$_{16}$$^{81}$BrN$_2$O$_5$ [M + NH$_4$]$^+$ 289.0218, found 289.0233.

**1,5-Dideoxy-2-*O*-tosyl-3-*O*-methyl-6-*O*-nitro-D-*arabino*-hexofuranose (30).** TsCl (116 mg, 1.057 mmol) was added to a stirred solution of **27** (200 mg, 0.965 mmol) in anhydrous pyridine (1 mL) at ambient temperature. After 16 h, the volatiles were evaporated and residue was partitioned between ice-cold AcOH/H$_2$O (1:99, 30 mL) and CHCl$_3$ (30 mL). The organic layer was separated, and the aqueous layer was extracted with CHCl$_3$ (30 mL). Combined organic phase was washed with ice-cold saturated NaHCO$_3$/H$_2$O (30 mL), brine (30 mL) and dried (Na$_2$SO$_4$), concentrated in vacuo and column chromatographed (EtOAc/hexane, 5:95 → 35:65) to give **30** (240 mg, 69%) as a colorless oil: $^1$H NMR δ 1.96–2.11 (m, 2H), 2.47 (s, 3H), 3.29 (s, 3H), 3.65 (td, *J* = 1.2, 4.4 Hz, 1H), 3.69–3.75 (m, 1H), 3.81 (dd, *J* = 4.1, 11.4 Hz, 1H), 3.92 (d, *J* = 11.4 Hz, 1H), 4.48–4.60 (m, 2H), 4.86 (td, *J* = 1.2, 4.1 Hz, 1H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.81 (d, *J* = 8.4 Hz, 2H). $^{13}$C NMR δ 21.6, 30.5, 58.0, 69.8, 71.3, 80.1, 83.1, 89.4, 127.8, 130.0, 133.4, 145.4; HRMS ESI/DART *m/z* calcd for C$_{14}$H$_{23}$N$_2$O$_8$S [M + NH$_4$]$^+$ 379.1170, found 379.1169.

**2-Chloro-1,2,5-trideoxy-3-*O*-methyl-6-*O*-nitro-D-*ribo*-hexofuranose (32).** Step a: TfCl (123 µL, 195 mg, 1.16 mmol) was added to a stirred solution of **27** (200 mg, 0.96 mmol) and DMAP (354 mg, 2.9 mmol) in anhydrous CH$_2$Cl$_2$ (2 mL) at 0 °C (ice-bath). After 1 h, the reaction mixture was partitioned between ice-cold AcOH/H$_2$O (1:99, 30 mL) and CH$_2$Cl$_2$ (30 mL). The aqueous layer was extracted with CH$_2$Cl$_2$ (30 mL) and the combined organic phase was washed with ice-cold saturated NaHCO$_3$/H$_2$O (30 mL), brine (30 mL) and dried (Na$_2$SO$_4$) to give **31** as a colorless oil (243 mg, 74%) of sufficient purity to be used in next step. Column chromatography (EtOAc/hexane, 5:95 → 30:70) gave pure sample of **31**: $^1$H NMR δ 2.01–2.09 (m, 1H), 2.09–2.19 (m, 1H), 3.46 (s, 3H), 3.75–3.82 (m, 2H), 3.98 (dd, *J* = 3.6, 12.1 Hz, 1H), 4.17 (d, *J* = 12.1 Hz, 1H), 4.53–4.65 (m, 2H), 5.26 (d, *J* = 3.5 Hz, 1H); *Step b*. A solution of crude **31** (100 mg, 0.29 mmol; from Step a) and dried LiCl (62.5 mg, 1.47 mmol) in DMF (1 mL) was stirred for 5 h at ambient temperature under N$_2$. Volatiles were evaporated and residue was partitioned between ice-cold saturated NaHCO$_3$/H$_2$O (15 mL) and EtOAc (15 mL). The separated organic phase was washed with brine (15 mL), dried (Na$_2$SO$_4$) and column chromatographed (EtOAc/hexane, 5:95 → 15:85) to give **32** (49 mg, 74%) as a colorless oil: $^1$H NMR δ 1.89–2.02 (m, 1H), 2.06–2.18 (m, 1H), 3.44 (s, 3H), 3.58 (dd, *J* = 5.1, 8.0 Hz, 1H), 3.95 (td, *J* = 4.1, 8.3 Hz, 1H), 4.05 (dd, *J* = 2.7, 10.8 Hz, 1H), 4.32 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.49 (td, *J* = 2.8, 5.0 Hz, 1H), 4.53–4.64 (m, 2H); $^{13}$C NMR δ 30.7, 57.6, 58.1, 69.9, 73.9, 76.1, 84.7; HRMS ESI/DART *m/z* calcd for C$_7$H$_{16}$$^{35}$ClN$_2$O$_5$ [M + NH$_4$]$^+$ 243.0742, found 243.0747; calcd for C$_7$H$_{16}$$^{37}$ClN$_2$O$_5$ [M + NH$_4$]$^+$ 245.0718, found 245.0716.

**2-Bromo-1,2,5-trideoxy-3-*O*-methyl-6-*O*-nitro-D-*ribo*-hexofuranose (33).** A solution of crude **31** (100 mg, 0.29 mmol; prepared as described for **32**, step a) and dried LiBr (77 mg, 0.88 mmol) in DMF (1 mL) was stirred for 5 h at ambient temperature under $N_2$. Volatiles were evaporated and residue was partitioned between ice-cold saturated $NaHCO_3/H_2O$ (15 mL) and EtOAc (15 mL). The separated organic phase was washed with brine (15 mL), dried ($Na_2SO_4$) and column chromatographed (EtOAc/hexane, 5:95 → 15:85) to give **33** (41 mg, 52%) as a colorless oil: ^{1}H NMR δ 1.90–2.0 (m, 1H), 2.06–2.16 (m, 1H), 3.39–3.45 (m, 4H), 3.97 (td, *J* = 4.2, 8.0 Hz, 1H), 4.20 (dd, *J* = 3.0, 11 Hz, 1H), 4.45 (dd, *J* = 4.8, 11.0 Hz, 1H), 4.50 (td, *J* = 2.9, 5.0 Hz, 1H), 4.53–4.64 (m, 2H); ^{13}C NMR δ 30.7, 49.5, 58.2, 69.9, 74.0, 76.5, 84.4; HRMS ESI/DART *m/z* calcd for $C_7H_{16}{}^{79}BrN_2O_5$ [M + NH$_4$]$^+$ 287.0237, found 287.0239; calcd for $C_7H_{16}{}^{81}BrN_2O_5$ [M + NH$_4$]$^+$ 289.0222, found 289.0218.

**Biomimetic studies with 6-*O*-nitro-1,4-anhydrohexitols. Typical Procedure**. A solution of **9** (20 mg, 0.06 mmol), Bu$_3$SnH (77 μL, 83 mg, 0.28 mmol), and AIBN (18 mg, 0.12 mmol) in dried toluene (2 mL) was deoxygenated (Ar) for 20 min and then heated at 95 °C for 1 h. Volatiles were evaporated carefully (at 25 °C and diminished pressure ~40 mmHg) and the residue was purified by column chromatography (EtOAc/hexane, 10:90 → 70:30) to give 1,2,5-trideoxy-D-*glycero*-hexofuranose-3-ulose **34a** in equilibrium mixture (~1:1) with cyclic hemiacetal **35a** (5 mg, 67%) as a colorless oil: HRMS ESI/DART *m/z* calcd for $C_6H_{11}O_3$ [M + H]$^+$ 131.0703, found 131.0707. Ketone **34a** had: ^{1}H NMR δ 1.84–1.93 (m, 1H), 1.95–2.06 (m, 2H), 2.15–2.27 (m, 2H), 3.74–3.85 (m, 2H), 3.88 (dd, *J* = 4.9, 7.4 Hz, 1H), 4.04–4.16 (m, 2H); ^{13}C NMR δ 32.9, 38.9, 59.8, 68.9, 78.6, 215.9. Hemiacetal **35a** had: 1.95–2.06 (m, 1H), 2.15–2.27 (m, 1H), 2.46–2.64 (m, 3H), 3.93–4.03 (m, 2H), 4.04–4.16 (m, 1H) 4.28 (dd, *J* = 2.27, 5.6 Hz, 1H), 4.37 (dt, *J* = 4.1, 9.2 Hz, 1H); ^{13}C NMR δ 32.1, 36.7, 64.6, 68.3, 85.7, 114.9.

Also isolated from the reaction mixture was 1,5-dideoxy-2-*O*-tosyl-D-*ribo*-hexofuranose (3.3 mg, 19%): ^{1}H NMR δ 1.81–1.94 (m, 2H), 2.46 (s, 3H), 3.74–3.85 (m, 4H), 3.86–3.93 (m, 1H), 4.12 (dd, *J* = 4.9, 11.2 Hz, 1H), 4.95 (dt, *J* = 3.0, 5.3 Hz, 1H), 7.38 & 7.82 (2 × d, *J* = 8.3 Hz, 2 × 2H).

Analogous treatment of **9** (20 mg, 0.06 mmol) with Bu$_3$SnD (77 μL, 83 mg, 0.28 mmol), instead of Bu$_3$SnH gave 2-deuterio epimers (2*R/S*, ~1:1) of **34b** in equilibrium mixture (~1:1) with **35b** (5.2 mg, 71%) as a colorless oil: ^{1}H NMR spectrum of **34b/35b** corresponded to this of the above **34a/35a** with reduction of the integrated intensity for the H2/2′ signal at δ 2.15–2.27 and 2.46–2.64 to approximately half and simplification of the H1/1′ signals at δ 4.04–4.16 (m, 1H) and 4.33–4.40 (m, 1H). ^{13}C NMR spectrum of **34b/35b** showed triplets at δ 36.7 and 38.9 (*J* = 20.1 Hz) for C2 carbons because of splitting to deuterium and two close peaks of equal intensity for each hemiacetal carbons. HRMS ESI/DART *m/z* calcd for $C_6H_{10}DO_3$ [M + H]$^+$ 132.0765, found 132.0768. Isotopic incorporation (MS) was calculated to be 85–95% for [^{2}H] isotopomers of **34b/35b** depends on the experiments. The ^{13}C NMR spectrum for the sample of **34b/35b** (2*R/S*, ~1:1, [^{2}H] incorporation ~85%) showed residual peaks at 38.9 ppm and 36.7 for the unlabeled **34a** and **35a**, respectively and isotopically upfield shifted carbon signals for **34b** (two sets of triplets of equal intensity at 38.60 and 38.63 ppm with $J_{C2-D}$ = 20.1 Hz) and **35b** two sets of triplets of equal intensity at 36.35 and 3.36 with $J_{C2-D}$ = 20.1 Hz), respectively.

**6-*O*-Benzoyl-1,2,5-trideoxy-D-*glycero*-hexofuranose-3-ulose (36a).** BzCl (23 μL, 28 mg, 0.2 mmol), pyridine (44 μL, 43 mg, 0.54 mmol), and DMAP (4 mg, 0.032 mmol) were added to a stirred solution of **34a/35a** (30 mg, 0.23 mmol), in $CH_2Cl_2$ (2 mL). Stirring was continued at ambient temperature for 3 h and MeOH (0.3 mL) was added. Volatiles were evaporated and the residue was chromatographed (EtOAc/hexane, 5:95 → 15:85) to give **36a** (22 mg, 81%) as an colorless oil: ^{1}H NMR δ 2.06–2.16 (m, 1H), 2.18–2.28 (m, 1H), 2.51 (dd, *J* = 6.50, 8.26 Hz, 2H), 3.90 (dd, *J* = 4.71, 7.0 Hz, 1H), 4.05–4.13 (m, 1H), 4.28–4.36 (m, 1H), 4.39–4.46 (m, 1H), 4.47–4.54 (m, 1H), 7.41–7.47(m, 2H), 7.56 (tt, *J* = 1.5, 7.4 Hz, 1H), 8.0 (d, *J* = 8.57 Hz, 2H); ^{13}C NMR δ 29.9, 36.8, 60.9, 64.7, 76.8, 128.5, 129.7, 130.2, 133.1, 166.5, 215.5; HRMS TOF/DART *m/z* calcd for $C_{13}H_{18}NO_4$ [M + NH$_4$]$^+$ 252.1230, found 252.1234.

**6-*O*-Benzoyl-2-deuterio-1,2,5-trideoxy-D-*glycero*-hexofuranose-3-ulose (36b).** Treatment of **34b/35b** (30 mg, 0.23 mmol) with BzCl, as described for **36a**, gave **36b** (12 mg, 67%) as a colorless oil: ^{1}H NMR

spectrum of **36b** corresponded to this of the above **36a** with reduction of the integrated intensity for the H2/2′ signal at δ 2.51 to half and simplification of the H1/1′ signals at 4.05–4.13 and 4.28–4.36. $^{13}$C NMR spectrum showed triplet at δ 36.4 ($J$ = 20.1 Hz) for C2 because of splitting to deuterium. HRMS ESI/DART *m/z* calcd for $C_{13}H_{13}DNaO_4$ [M + Na]$^+$ 258.0847, found 258.0836.

**Biomimetic studies with 3-*O*-methyl-6-*O*-nitro-1,4-anhydrohexitols. 2-(2-Hydroxyethyl)-3-methoxyfuran (37)**. A solution of **25** (25 mg, 0.069 mmol), Bu$_3$SnH (92 μL, 100 mg, 0.34 mmol), and AIBN (22.7 mg, 0.14 mmol) in dried toluene (2 mL), was deoxygenated (Ar) for 20 min and then heated at 95 °C for 1.5 h. Volatiles were evaporated and the residue was purified by column chromatography (EtOAc/hexane, 10:90 → 75:25) to give **37** (6.2 mg, 63%) followed by 1,5-dideoxy-2-*O*-tosyl-3-*O*-methyl-ᴅ-*ribo*-hexofuranose (**38**, 4.8 mg, 22%) as a colorless oils. Compound **37** had: $^1$H NMR δ 2.89 (t, $J$ = 6.0 Hz, 2H), 3.76 (s, 3H), 3.86 (t, $J$ = 6.0 Hz, 2H), 6.31 (d, $J$ = 2.1 Hz, 1H), 7.16 (d, $J$ = 2.1 Hz, 1H); $^{13}$C NMR δ 29.3, 59.4, 60.9, 102.9, 136.7, 139.7, 144.3; HRMS ESI/FT-ICR *m/z* calcd for $C_7H_{11}O_3$ [M + H]$^+$ 143.0702, found 143.0701. Compound **38** had: $^1$H NMR δ 1.74–1.84 (m, 1H), 1.85–1.94 (m, 1H), 2.29 (t, $J$ = 5.9 Hz, 1H), 2.46 (s, 3H), 3.32 (s, 3H), 3.49 (dd, $J$ = 4.9, 8.3 Hz, 1H), 3.72–3.79 (m, 2H), 3.85–3.94 (m, 2H), 4.07 (dd, $J$ = 4.7, 11.3 Hz, 1H), 5.11 (dt, $J$ = 2.4, 4.8 Hz, 1H), 7.36 (d, $J$ = 8.1 Hz, 2H), 7.83 (d, $J$ = 8.1 Hz, 2H); $^{13}$C NMR δ 21.6, 35.6, 58.3, 60.6, 70.9, 76.5, 79.1, 83.8, 127.8, 129.9, 133.8, 145.1; HRMS ESI/DART *m/z* calcd for $C_{14}H_{21}O_6S$ [M + H]$^+$ 317.1053, found 317.1055.

Analogous treatment of **25** with Bu$_3$SnD gave **37** (6.0 mg, 61%) and (**38**, 4.8 mg, 22%) with spectroscopic data as above.

Treatment of **30** (25 mg, 0.069 mmol) with Bu$_3$SnH, as described for **37**, gave **37** (5.0 mg, 51%) with data as above and 1,5-dideoxy-2-*O*-tosyl-3-*O*-methyl-ᴅ-*arabino*-hexofuranose **39** (8.3 mg, 38%) as a colorless oil: $^1$H NMR δ 1.86–1.94 (m, 2H), 2.04–2.11 (m, 1H), 2.47 (s, 3H), 3.31 (s, 3H), 3.70 (dt, $J$ = 1.2, 5.0 Hz, 1H), 3.73–3.82 (m, 3H), 3.83 (d, $J$ = 4.3 Hz, 1H), 3.93 (d, $J$ = 11.7 Hz, 1H), 4.88 (dt, $J$ = 1.3, 4.2 Hz, 1H), 7.37 (d, $J$ = 8.4 Hz, 2H), 7.81 (d, $J$ = 8.4 Hz, 2H); $^{13}$C NMR δ 21.6, 35.3, 58.0, 60.5, 71.3, 82.7, 83.4, 89.7, 127.8, 130.0, 133.5, 145.3; HRMS ESI/DART *m/z* calcd for $C_{14}H_{21}O_6S$ [M + H]$^+$ 317.1053, found 317.1050.

Analogous treatment of **30** with Bu$_3$SnD gave **37** (4.9 mg, 50%) and **39** (8.2 mg, 38%) with spectroscopic data as above.

**1,2,5-Trideoxy-3-*O*-methyl-ᴅ-*glycero*-hex-2-enofuranose (40). Typical Procedure.** A solution of **29** (20 mg, 0.074 mmol), Bu$_3$SnD (99 μL, 108 mg, 0.369 mmol), and AIBN (24 mg, 0.146 mmol) in dried toluene (2 mL), was deoxygenated (Ar) for 20 min and then heated at 95 °C for 2 h. Volatiles were evaporated and the residue was purified by column chromatography (EtOAc/hexane, 10:90 → 70:30) to give **40** [22] (5.0 mg, 47%) as a colorless oil: $^1$H NMR δ 1.73–1.87 (m, 1H), 1.94–2.09 (m, 1H), 2.58 (t, $J$ = 5.6 Hz, 1H), 3.68 (s, 3H), 3.76–3.82 (m, 2H), 4.60–4.70 (m, 3H), 4.73–4.79 (m, 1H); $^{13}$C NMR δ 35.6, 57.6, 60.6, 72.8, 81.2, 90.2, 157.7; HRMS ESI/DART *m/z* calcd for $C_7H_{16}NO_3$ [M + NH$_4$]$^+$ 162.1125, found 162.1131.

**Comparison of Reaction Rates of 9, 13 or 18 with Bu$_3$SnH.** Independent solutions of 0.057 mmol samples of **9**, **13** and **18** in toluene–$d_8$ (2.0 mL) were treated with 5 molar equiv of Bu$_3$SnH and 2 molar equiv of AIBN at 75 °C. Aliquots of the individual reaction mixtures (0.3 mL) were diluted in toluene–$d_8$ (0.2 mL) and directly analyzed by $^1$H NMR. The **34a/35a** (1:1)/starting material ratios were obtained by integrating disappearance of the peak at 4.55 ppm for H2 of **9** or **18** or at 3.96 ppm for H6 of **13** and appearance of the peak at 4.10 ppm for the H4 of **34a**. The determinations were conducted under the pseudo-first-order conditions:

$$k_1 t = -2.303 \log(C/C_o) + a$$

where $C/C_o$ is the ratio of the concentration of starting material **9**, **18**, or **13** in the mixture at time $t$ to the initial concentration of starting material. Values of the term $[-\log(C/C_o)]$ were plotted against $[t(\text{min})k(\text{s}^{-1}) = k_1 \ (\text{min}^{-1})/3600]$.

## 5. Summary and Conclusions

Remarkable changes between anionic and radical elimination mechanisms occurred with our 1,4-anhydrofuranitols. All 2-(bromo, chloro, and tosylate) epimers that contained a 3-hydroxyl group underwent two-electron elimination of bromide, chloride, or tosylate ions to give the same furanone **34a** or deuterated furanone **34b**. The inductively donating C1 of the furanitols allows for the elimination of an anion from C2 upon generation of a radical center at C3. Loss of the 3-hydroxyl proton produces a 3-oxo-C2 radical, which abstracts hydrogen from $HSnBu_3$ or deuterium from $DSnBu_3$.

All of the 3-*O*-methyl-2-bromo- and 2-chloro analogues underwent one-electron elimination of a bromine or chlorine atom to produce 2-(2-hydroxyethyl)-3-methoxy-2,5-dihydrofuran **40**. No deuterium incorporation occurred in these cases. The 3-*O*-methyl-2-*O*-tosyl epimers underwent more drastic fragmentation upon generation of a C3 radical. Elimination of toluenesulfonic acid from C2/C1 and abstraction of hydrogen from C4 produced the aromatized 2-(2-hydroxyethyl)-3-methoxyfuran **37**.

The inductively negative anomeric carbon (C1′) in nucleos(t)ides disfavors elimination of a chloride anion from C2′. Loss of Cl• followed by 1,4-elimination of the 3′-hydroxyl proton and base gives the unlabeled 2-(2-hydroxyethyl)-3(2*H*)-furanone (path b, Figure 4). The abstraction of deuterium from $DSnBu_3$ by Cl• provides a chain propagation step and so no label is incorporated into the furanone product.

By contrast, dissociation of a prohibitively high-energy tosyloxy radical is precluded so that departure of a tosylate anion from C2′ occurs. Loss of the 3′-hydroxyl proton gives a 3′-oxo-C2′ radical, which abstracts deuterium from $DSnBu_3$ and undergoes elimination of H/D and nucleobase to produce 4-deuterio-2-(2-hydroxyethyl)-3(2*H*)-furanone (path a, Figure 4).

Our combined results with nucleoside and anhydroalditol models provide data for plausible mechanistic rationalization of the two-electron elimination of hydrogen-bonded water from substrate nucleoside di(or tri)phosphates, and for one-electron dissociation of a chlorine atom from 2′-chloro-2′-deoxynucleoside di(or tri)phosphate inactivators of ribonucleotide reductases and the MoaA enzyme. Such Cl• radicals could react with active site components and contribute to enzyme inactivation.

Theoretical studies [18,19,44] employ major assumptions and calculation simplifications relative to actual biological systems. Mechanistic hypotheses based on reactions executed by modified enzymes [26,46] also involve unnatural "biomimetic" models—whether prepared by chemical synthesis or molecular biology. Combination of theoretical, biochemical, and biomimetic modeling provides more insightful approximations that any one of the individual models. Results of our present studies add clarity to hypotheses postulated for the radical chemistry-based inactivation of RNRs [30] and MoaA [32].

## References and Note

1. Stubbe, J.; van der Donk, W.A. Ribonucleotide reductases: Radical enzymes with suicidal tendencies. *Chem. Biol.* **1995**, *2*, 793–801.
2. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. *Curr. Cancer Drug Targets* **2006**, *6*, 409–431. [CrossRef]
3. Cerqueira, N.M.F.S.A.; Fernandes, P.A.; Ramos, M.J. Ribonucleotide reductase: A critical enzyme for cancer chemotherapy and antiviral agents. *Recent Pat. Anticancer Drug Discov.* **2007**, *2*, 11–29. [CrossRef]

4.   Ator, M.A.; Stubbe, J. Mechanism of inactivation of Escherichia coli ribonucleotide reductase by 2′-chloro-2′-deoxyuridine 5′-diphosphate: Evidence for generation of a 2′-deoxy-3′-ketonucleotide via a net 1,2 hydrogen shift. *Biochemistry* **1985**, *24*, 7214–7221. [CrossRef]

5.   Sjoberg, B.M.; Graslund, A.; Eckstein, F. A substrate radical intermediate in the reaction between ribonucleotide reductase from Escherichia coli and 2′-azido-2′-deoxynucleoside diphosphates. *J. Biol. Chem.* **1983**, *258*, 8060–8067.

6.   Salowe, S.; Bollinger, J.M., Jr.; Ator, M.; Stubbe, J.; McCracken, J.; Peisach, J.; Samano, M.C.; Robins, M.J. Alternative model for mechanism-based inhibition of Escherichia coli ribonucleotide reductase by 2′-azido-2′-deoxyuridine 5′-diphosphate. *Biochemistry* **1993**, *32*, 12749–12760. [CrossRef]

7.   van der Donk, W.A.; Stubbe, J.; Gerfen, G.J.; Bellew, B.F.; Griffin, R.G. EPR Investigations of the Inactivation of E. coli Ribonucleotide Reductase with 2′-Azido-2′-deoxyuridine 5′-Diphosphate: Evidence for the Involvement of the Thiyl Radical of C225-R1. *J. Am. Chem. Soc.* **1995**, *117*, 8908–8916. [CrossRef]

8.   Fritscher, J.; Artin, E.; Wnuk, S.; Bar, G.; Robblee, J.H.; Kacprzak, S.; Kaupp, M.; Griffin, R.G.; Bennati, M.; Stubbe, J. Structure of the Nitrogen-Centered Radical Formed during Inactivation of E. coli Ribonucleotide Reductase by 2′-Azido-2′-deoxyuridine-5′-diphosphate: Trapping of the 3′-Ketonucleotide. *J. Am. Chem. Soc.* **2005**, *127*, 7729–7738. [CrossRef]

9.   Manegold, C. Gemcitabine (Gemzar) in non-small cell lung cancer. *Expert Rev. Anticancer Ther.* **2004**, *4*, 345–360. [CrossRef]

10.  Jordheim, L.P.; Durantel, D.; Zoulim, F.; Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. *Nat. Rev. Drug. Discov.* **2013**, *12*, 1474–1776. [CrossRef]

11.  Mao, S.S.; Holler, T.P.; Yu, G.X.; Bollinger, J.M., Jr.; Booker, S.; Johnston, M.I.; Stubbe, J. A model for the role of multiple cysteine residues involved in ribonucleotide reduction: Amazing and still confusing. *Biochemistry* **1992**, *31*, 9733–9743. [CrossRef]

12.  Mao, S.S.; Yu, G.X.; Chalfoun, D.; Stubbe, J. Characterization of C439SR1, a mutant of Escherichia coli ribonucleotide diphosphate reductase: Evidence that C439 is a residue essential for nucleotide reduction and C439SR1 is a protein possessing novel thioredoxin-like activity. *Biochemistry* **1992**, *31*, 9752–9759. [CrossRef]

13.  Baker, C.H.; Banzon, J.; Bollinger, J.M.; Stubbe, J.; Samano, V.; Robins, M.J.; Lippert, B.; Jarvi, E.; Resvick, R. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase. *J. Med. Chem.* **1991**, *34*, 1879–1884. [CrossRef]

14.  Artin, E.; Wang, J.; Lohman, G.J.S.; Yokoyama, K.; Yu, G.; Griffin, R.G.; Bar, G.; Stubbe, J. Insight into the Mechanism of Inactivation of Ribonucleotide Reductase by Gemcitabine 5′-Diphosphate in the Presence or Absence of Reductant. *Biochemistry* **2009**, *48*, 11622–11629. [CrossRef]

15.  Wang, J.; Lohman, G.J.S.; Stubbe, J. Mechanism of Inactivation of Human Ribonucleotide Reductase with p53R2 by Gemcitabine 5′-Diphosphate. *Biochemistry* **2009**, *48*, 11612–11621. [CrossRef]

16.  Lohman, G.J.S.; Stubbe, J. Inactivation of Lactobacillus leichmannii Ribonucleotide Reductase by 2′,2′-Difluoro-2′-deoxycytidine 5′-Triphosphate: Covalent Modification. *Biochemistry* **2010**, *49*, 1404–1417. [CrossRef]

17.  Lohman, G.J.S.; Gerfen, G.J.; Stubbe, J. Inactivation of Lactobacillus leichmannii Ribonucleotide Reductase by 2′,2′-Difluoro-2′-deoxycytidine 5′-Triphosphate: Adenosylcobalamin Destruction and Formation of a Nucleotide-Based Radical. *Biochemistry* **2010**, *49*, 1396–1403. [CrossRef]

18.  Siegbahn, P.E.M. Theoretical Study of the Substrate Mechanism of Ribonucleotide Reductase. *J. Am. Chem. Soc.* **1998**, *120*, 8417–8429. [CrossRef]

19.  Fernandes, P.A.; Ramos, M.J. Theoretical Studies on the Mode of Inhibition of Ribonucleotide Reductase by 2′-Substituted Substrate Analogues. *Chem. Eur. J.* **2003**, *9*, 5916–5925. [CrossRef]

20.  Lenz, R.; Giese, B. Studies on the Mechanism of Ribonucleotide Reductases. *J. Am. Chem. Soc.* **1997**, *119*, 2784–2794. [CrossRef]

21.  Robins, M.J.; Guo, Z.; Samano, M.C.; Wnuk, S.F. Biomimetic Simulation of Free Radical-Initiated Cascade Reactions Postulated To Occur at the Active Site of Ribonucleotide Reductases. *J. Am. Chem. Soc.* **1999**, *121*, 1425–1433. [CrossRef]

22.  Robins, M.J.; Ewing, G.J. Biomimetic Modeling of the First Substrate Reaction at the Active Site of Ribonucleotide Reductases. Abstraction of H3′ by a Thiyl Free Radical. *J. Am. Chem. Soc.* **1999**, *121*, 5823–5824. [CrossRef]

23. van der Donk, W.A.; Yu, G.; Silva, D.J.; Stubbe, J.; McCarthy, J.R.; Jarvi, E.T.; Matthews, D.P.; Resvick, R.J.; Wagner, E. Inactivation of Ribonucleotide Reductase by (E)-2′-Fluoromethylene-2′-deoxycytidine 5′-Diphosphate: A Paradigm for Nucleotide Mechanism-Based Inhibitors. *Biochemistry* **1996**, *35*, 8381–8391. [CrossRef] [PubMed]

24. Gerfen, G.J.; van der Donk, W.A.; Yu, G.; McCarthy, J.R.; Jarvi, E.T.; Matthews, D.P.; Farrar, C.; Griffin, R.G.; Stubbe, J. Characterization of a Substrate-Derived Radical Detected during the Inactivation of Ribonucleotide Reductase from Escherichia coli by 2′-Fluoromethylene-2′-deoxycytidine 5′-Diphosphate. *J. Am. Chem. Soc.* **1998**, *120*, 3823–3835. [CrossRef]

25. Wnuk, S.F.; Penjarla, J.A.K.; Dang, T.P.; Mebel, A.M.; Nauser, T.; Schöneich, C. Pulse radiolysis experiments with a 1,4-anhydro-5-deoxy-6-thio-D-ribo-hexofuranitol allowed to detect the ribosyl-based carbon-centered radical(s) and to measure rate constant for the H abstraction(s) which correlates with the internal H atom abstractions from C1, C2, C3 or C4 by the thiyl radical. *Collect. Czech. Chem. Commun.* **2011**, *76*, 1223–1238.

26. Persson, A.L.; Sahlin, M.; Sjoberg, B.-M. Cysteinyl and substrate radical formation in active site mutant E441Q of Escherichia coli class I ribonucleotide reductase. *J. Biol. Chem.* **1998**, *273*, 31016–31020. [CrossRef]

27. Lawrence, C.C.; Bennati, M.; Obias, H.V.; Bar, G.; Griffin, R.G.; Stubbe, J. High-field EPR detection of a disulfide radical anion in the reduction of cytidine 5′-diphosphate by the E441Q R1 mutant of Escherichia coli ribonucleotide reductase. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 8979–8984. [CrossRef]

28. Zipse, H.; Artin, E.; Wnuk, S.; Lohman, G.J.S.; Martino, D.; Griffin, R.G.; Kacprzak, S.; Kaupp, M.; Hoffman, B.; Bennati, M.; et al. Structure of the Nucleotide Radical Formed during Reaction of CDP/TTP with the E441Q-α2β2 of *E. coli* Ribonucleotide Reductase. *J. Am. Chem. Soc.* **2009**, *131*, 200–211. [CrossRef]

29. Robins, M.J.; Guo, Z.; Wnuk, S.F. Elimination of Chlorine (Radical) or Tosylate (Anion) from C2′ of Nucleoside C3′ Free Radicals as Model Reactions Postulated To Occur at the Active Site of Ribonucleotide Reductases. *J. Am. Chem. Soc.* **1997**, *119*, 3637–3638. [CrossRef]

30. Robins, M.J.; Guo, Z.; Samano, M.C.; Wnuk, S.F. Biomimetic Modeling of the Decomposition of 2′-Chloro-2′-deoxynucleotides by Ribonucleotide Reductases To Give 3(2H)-Furanones Which Can Effect Mechanism-Based Inactivation by Michael-Type Alkylation. *J. Am. Chem. Soc.* **1996**, *118*, 11317–11318. [CrossRef]

31. Robins, M.J.; Wnuk, S.F.; Hernandez-Thirring, A.E.; Samano, M.C. Nucleic Acid-Related Compounds. 91. Biomimetic Reactions Are in Harmony with Loss of 2′-Substituents as Free Radicals (Not Anions) during Mechanism-Based Inactivation of Ribonucleotide Reductases. Differential Interactions of Azide, Halogen, and Alkylthio Groups with Tributylstannane and Triphenylsilane. *J. Am. Chem. Soc.* **1996**, *118*, 11341–11348.

32. Mehta, A.P.; Abdelwahed, S.H.; Xu, H.; Begley, T.P. Molybdopterin Biosynthesis: Trapping of Intermediates for the MoaA-Catalyzed Reaction Using 2′-DeoxyGTP and 2′-ChloroGTP as Substrate Analogues. *J. Am. Chem. Soc.* **2014**, *136*, 10609–10614. [CrossRef] [PubMed]

33. Rolf, D.; Gray, G.R. Reductive cleavage of glycosides. *J. Am. Chem. Soc.* **1982**, *104*, 3539–3541. [CrossRef]

34. Ewing, G.J.; Robins, M.J. An Efficient One-Stage Deprotection/Reduction of 1,2-*O*-Isopropylidene Furanoses to the Corresponding Tetrahydrofurans. *Org. Lett.* **1999**, *1*, 635–636. [CrossRef]

35. Throughout this manuscript the reported 1-deoxyhomoribose derivatives are named as 1,5-dideoxy-D-*ribo*-hexofuranose derivatives rather than 1,4-anhydro-5-deoxy-D-*ribo*-hexitols in order to be consistent with the names and stereochemistry used in the literature (see Refs 21, 29 and 30) and discussion in the text (Figure 4) for their homonucleoside analogues.

36. Wagner, D.; Verheyden, J.P.H.; Moffatt, J.G. Preparation and synthetic utility of some organo tin derivatives of nucleosides. *J. Org. Chem.* **1974**, *39*, 24–30.

37. Guo, Z.; Samano, M.C.; Krzykawski, J.W.; Wnuk, S.F.; Ewing, G.J.; Robins, M.J. Biomimetic modeling of the abstraction of H3′ by ribonucleotide reductases. 1,5-hydrogen atom transfer of H3 to aminyl and oxyl, but not thiyl, free radicals in homo-ribofuranose derivatives. *Tetrahedron* **1999**, *55*, 5705–5718.

38. Holy, A. Nucleic acid components and their analogues. CLIII. Preparation of 2′-deoxy-L-ribonucleosides of the pyrimidine series. *Collect. Czech. Chem. Commun.* **1972**, *37*, 4072–4087. [CrossRef]

39. Barton, D.H.R.; Beaton, J.M.; Geller, L.E.; Pechet, M.M. A New Photochemical Reaction1. *J. Am. Chem. Soc.* **1961**, *83*, 4076–4083. [CrossRef]

40. Wagner, P.J.; Lindstrom, M.J.; Sedon, J.H.; Ward, D.R. Photochemistry of delta.-haloketones: Anchimeric assistance in triplet-state gamma.-hydrogen abstraction and beta.-elimination of halogen atoms from the resulting diradicals. *J. Am. Chem. Soc.* **1981**, *103*, 3842–3849.

41. Lopez, J.C.; Alonso, R.; Fraser-Reid, B. Alkoxyl radicals in 1,5-hydrogen shifts for site-specific, stereocontrolled alkylation of carbohydrates. *J. Am. Chem. Soc.* **1989**, *111*, 6471–6473. [CrossRef]

42. Hansske, F.; Robins, M.J. Nucleic acid related compounds. 45. A deoxygenative [1,2]-hydride shift rearrangement converting cyclic cis-diol monotosylates to inverted secondary alcohols. *J. Am. Chem. Soc.* **1983**, *105*, 6736–6737.

43. Robins, M.J.; Nowak, I.; Wnuk, S.F.; Hansske, F.; Madej, D. Deoxygenative [1,2]-Hydride Shift Rearrangements in Nucleoside and Sugar Chemistry: Analogy with the [1,2]-Electron Shift in the Deoxygenation of Ribonucleotides by Ribonucleotide Reductases1. *J. Org. Chem.* **2007**, *72*, 8216–8221. [CrossRef] [PubMed]

44. Zipse, H. The Addition of Water to Ethylene and trans-Butene Radical Cation. Model Systems for the Reaction of Alkene Radical Cations with Nucleophiles. *J. Am. Chem. Soc.* **1995**, *117*, 11798–11806.

45. Cavrini, V.; Garuti, L.; Giovanninetti, G.; Amorosa, M.; Mannini Palenzona, A.; Defaye, J. Homoanalogues of pyrimidine nucleosides. XII. 3,6-anhydro-1,2-bis-desoxy-1-(pyrimidin- and 5-halopyrimidin-1-yl)-D-arabinohexitols; 3,6-anhydro-1-desoxy-1(5-halopyrimidin-1-yl)-D-glucitols. *Il Farm. Ed. Sci.* **1979**, *34*, 635–645.

46. Achrainer, F.; Zipse, H. Transfer Hydrogenation in Open-Shell Nucleotides—A Theoretical Survey. *Molecules* **2014**, *19*, 21489–21505. [CrossRef]

**Sample Availability:** Samples of the compounds are not available from the authors.